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Heng Zhao 
 
THE EFFECTS OF DIETARY POLYUNSATURATED FATTY ACIDS ON 
PROSTATE CANCER-PROTEOMIC AND PHOSPHOPROTEOMIC STUDIES 
 
This dissertation studies the effects of fatty acids on prostate cancer.  Prostate 
cancer is one of the most common malignant diseases in males in the U.S.  Because of 
the slow progression of this disease, early intervention methods, especially, dietary fatty 
acid interventions are considered very important to control the disease in early stages.  
This study describes how the depletion of the enzyme for endogenous fatty acid synthesis, 
fatty acid synthase, influences the expression of enzymes that metabolize dietary fatty 
acids and show how dietary fatty acids affect prostate cancer protein expression and 
function.  Fatty acid synthase is an oncoprotein overexpressed in prostate cancer and its 
expression is suppressed with omega-3 fatty acid treatment.  This study finds that the 
depletion of fatty acid synthase by siRNA knockdown induces suppression of 
cyclooxygenase-2 and fatty acid desaturase-1.  Our results also show that fish oil (omega-
3 fatty acid), but not oleic acid (omega-9 fatty acid), suppresses prostate cancer cell 
viability.  Assessment of fatty acid synthesis activity indicates that oleic acid is a more 
potent inhibitor than fish oil of de novo fatty acid biosynthesis.  In addition, the inhibition 
of its activity occurs over several days while its effects on cell viability occur within 24 
hours.  To better understand this relationship, label free LC-MS/MS based mass 
spectrometry was carried out to determine global proteomic and phosphoproteomic 
profiles of the prostate cell line PC3, with longitudinal treatment with fish oil or oleic 
acid.  With short-term fish oil treatment, sequestosome-1was elevated.  Prolonged 
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treatment induced downregulation of microseminoprotein, a proinflammation factor, as 
well as proteins in the glycolysis pathway.  In the phosphoproteomics study, we 
confidently identified 828 phosphopeptides from 361 phosphoproteins.  Quantitative 
comparison between fish oil or oleic acid treated groups and the untreated group suggests 
that the fish oil induces changes in phosphorylation of proteins involved in the pathways 
associated with cell viability and metabolic processes, with fish oil inducing significant 
decreases in the levels of phospho-PDHA1Ser232 and phospho-PDHA1Ser300 and they were 
accompanied by an increase in PDH activity, suggesting a role for n-3 polyunsaturated 
fatty acids in controlling the balance between lipid and glucose oxidation.  
 
Mu Wang, Ph.D., Chair 
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Chapter 1 Introduction 
1 Prostate function 
The prostate, an important accessary organ in the male reproductive system, is a 
walnut size gland located very close to the bladder and weights around 30 grams.  The 
prostate gland secretes prostatic fluid, composing about 30% of the final volume of 
seminal fluid.  The urethra connects the bladder and the penis and passes through the 
center of the prostate.  During ejaculation, when sperm travel from the testes and pass 
through the prostate, the muscle of the prostate contracts to secrete prostatic fluid, which 
forms semen with the sperm-containing fluid in urethra.  The prostate consists of the 
peripheral zone, the central zone, and the transition zone and the epithelial cells of the 
gland are surrounded by the stroma.  The peripheral zone occupies the major part of 
prostate and 70%-80% prostate cancer (PCa) occurs in this region.  The function of 
prostate secretion is to liquefy semen and nourish sperm and by providing various 
elements, including proteolytic enzymes such as, prostate specific antigen (PSA) and ions 
including citrate and zinc.  PSA belongs to the kallikrein-related peptidase family and 
functions to dissolve seminal coagulum and cervical mucus, allowing sperm to move 
freely to enter the uterus [1, 2].  Zinc is reported to help stabilize chromatin in sperm cells 
by maintaining the chromatin structure [3].  It is also known that high levels of zinc can 
increase the concentration of citrate [4], which is an important component of prostatic 
fluid.  It is reported that concentration, transportation and metabolism of citrate are 
altered in PCa [5].  The prostate’s function is very important to men’s health and fertility.  
However, prostate disease is one of the most common health issues in men.  For the 
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majority of men, prostatitis, benign prostatic hyperplasia (BPH), and/or prostate cancer, 
may develop some time during their lifetime.  
 
2 Prostate cancer incidence and risk factors 
PCa is currently the second most common cancer occurring in men [6] with an 
estimated 220,800 new cases diagnosed and 27,540 deaths in 2015 (NCI SEER Stat Fact 
Sheets) [7].  Death due to PCa accounts for 1%-2% of the total mortality in men.  PCa 
related morbidity largely reduces quality of life by causing erectile dysfunction and 
urinary inconsistency.  The risk of developing PCa is currently one in six men (16.7%) 
and the overall risk of death due to metastatic PCa is about 2.8% with the disease 
progressing relatively slowly to advanced stages [8] and in many cases, the disease 
develops very slowly and without symptoms [9].  Although, PCa occurrence is as high as 
85% in men older than 80 years of age, it is rare in men under 40 [10].   
Both endogenous and exogenous factors contribute to PCa risks.  Genetic 
influence: Familial clustering is observed in PCa occurrence. Having close family 
members, such as father or brothers, developing prostate cancer, especially diagnosed 
before 65 years old, indicates a higher PCa risk [11], which suggests PCa is influenced 
genetically.  Studies on susceptibility genes [12, 13] and single nucleotide 
polymorphisms (SNPs) [14] have been carried out and showed that these factors can only 
explain part of the familial risks.  Hormone influence: Hormones, androgens [15, 16] 
and estrogens [17, 18], may affect PCa incidence but the study conclusions are 
inconsistent and controversial.  Inflammatory influence: Whether chronic inflammation 
is etiologically related to PCa has also been studied.  In some studies, men with history of 
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prostatitis and sexually transmitted diseases have been shown to have a higher PCa risk 
[19, 20], but some other studies show no association between transmitted sexual 
infections and PCa [21, 22].  Prostate inflammation and PCa may be linked as some 
molecules are found to be critical for both prostatitis and PCa development, including 
certain fatty acids, nutrients and proinflammatory cytokines [23, 24].  Proliferative 
inflammatory atrophy (PIA) in the prostate most often occurs in parallel with 
inflammation.  PIA lesions are thought to develop with epithelial proliferation in 
response to inflammatory injury and are believed to be a potential precursor to 
adenocarcinoma [25]. 
Influence from environment and behavioral risk: Prostate risk also varies 
between ethnic populations such that African-American men have a much higher risk of 
developing PCa than Asians.  Noticeably, Asian men living in the Unites States have 
lower PCa risk than Caucasians and African Americans but higher risk when compared to 
Asian men living in Asia [26]. These facts suggest PCa may be influenced by the 
combination of various factors and both genetic and dietary/environmental factors may 
contribute to cancer occurrence.  Other factors, such as smoking [27], vasectomy [28], 
obesity [29], sexually transmitted disease [30] and inflammation [23] have also been 
studied but conclusions are inconsistent among the studies.  
 
3 Prostate cancer diagnosis and treatment 
PCa develops so slowly and many men with this disease have no symptoms when 
diagnosed. Screening helps patients be aware of the possible existence of PCa in early 
stages and screening is thought to decrease the number of men that are diagnosed with 
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PCa that has already progressed to advanced stages. Considering in many cases prostate 
cancer will remain indolent, patients with low risk PCa, or elderly patients with a family 
history of the disease, regular active surveillance is recommended to determine whether 
further treatment is necessary.  PCa screening includes digital rectal examination (DRE) 
and PSA test.  The prostate is located in front of the rectum and DRE detects unusual 
growth in the prostate.  The PSA test is used to detect elevated serum protein levels, and 
PSA between 4ng/ml and 10ng/ml usually results in additional PCa surveillance and 
screening.  In men diagnosed with PCa, a rapid rise in blood PSA levels may suggest 
disease progression or cancer relapse after treatment.  However, controversies also exist 
concerning whether PSA screening is necessary. Although screening may help reduce the 
mortality caused by PCa by discovering the disease in early stages, many men that are 
screened still develop advanced PCa and die from it.  Additionally, false positive results, 
or indolent tumors may never need intervention.  Because of its poor predictive accuracy 
[31], PSA screening may result in over-diagnosis and unnecessary aggressive treatments, 
which may impair a patient’s health and life.   
A positive DRE combined with PSA elevation typically is followed by a prostate 
biopsy.  Biopsy results are reported as Gleason scores.  Pathologists categorize PCa tissue 
by five different patterns, ranging from well differentiated  (pattern 1) to poorly 
differentiated (pattern 5) carcinoma cells.  Gleason Scores are calculated by the sum of 
the numbers of primary and secondary common patterns (in some systems, primary and 
the highest grade).  Other diagnostic parameters, such as PSA and DRE, and ultrasound 
will be combined with biopsy results to help to decide the next steps of treatment.  Active 
surveillance is an option when the risk of treatment outweighs the risk of non-treatment, 
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especially when patients are physically weak and advanced in age, or there are no 
symptoms observed.  Additionally, staging systems, which define whether the cancer has 
metastasized to other parts of the body, also guides the treatment decisions.  Surgery, 
such as radical prostatectomy can be performed on stage T1 and T2 tumors, characterized 
by tumor growth limited to the gland and confined within the prostate capsule. For the 
majority of patients with localized PCa, surgery or radiation treatment is curative.  
However, in a subset of patients, the disease progresses to a more advanced stage, and 
becomes life threatening.   
Hormone therapy may be used in patients with advanced prostate cancer, when 
tumor penetration is beyond the capsule, characterized by stage T3 and T4, or if cancer 
recurs after radiation or radical surgery, or when metastasis occurs (N1 stage, M1 stage, 
when tumors spread to lung, bone, lymph nodes, brain or other parts of the body) in 
combination with rapid PSA level increases.   
Androgen is required for growth of the gland in almost every stage of prostate 
development.  Testosterone and its more potent derivative dihydrotestosterone (DHT) 
binds to the androgen receptor (AR) and enters the nuclei to function as a transcription 
factor to regulate expression of multiple genes [32]. In most cases, PCa cell growth is 
also dependent on androgen stimulation, mainly induced by testosterone and DHT, 
however, high androgen serum levels are not positively associated with high PCa risk 
[16].  Hormone deprivation treatment can control PCa progression. Hormone therapies 
used to suppress the androgen pathway include surgical castration and chemical 
castration, such as luteinizing hormone-releasing hormone analogs, androgen-suppressing 
drugs and AR antagonists [33].  Besides these therapies, radiation therapy can also be 
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applied in some situations to minimize the tumor size.  In some cases PCa can develop 
into more advanced stages and PCa cells can grow despite hormone blockade.  Castration 
resistance may be attained through several mechanisms [34]: over expressed/ amplified 
AR [35, 36], hypersensitive or mutated AR [37], or constitutively active truncation [38] 
of AR gene/protein or over production of androgen in prostate cells [39].  PCa cells can 
also become castration-resistant when AR is over-activated by growth factor/cytokines 
[40], or some AR co-activators, like AIB1 [41] and ARA55 [42].  
When PCa metastasizes to other organs and tissues and cancer cell growth 
becomes hormone-refractory, chemotherapy drugs, such as docetaxel and cabazitaxel, are 
most often used to extend patients’ life and relieve some symptoms.  However, in this 
stage of advanced PCa, especially when the metastasis is combined with castration 
resistance, PCa is usually incurable.  To date no definitive factors have been associated 
with PCa development and progression and no curative therapy exists for advanced 
disease.  The slow progression of the disease and the lethality of advanced cases make the 
prevention and control in early stages critically important.  Given the long latency period 
of PCa progression coupled with the close association between incidence and aging, 
therapies that slow disease progression would help eliminate the need for surgery or 
radiation and prevent metastatic spread.   
 
4 Fatty acid synthase (FASN) and prostate cancer 
1) Expression and functions of FASN in cancer 
Lipogenesis is considered to be both pro-inflammatory [43] and pro-oncogenic 
[44].  In many cancers, lipogenesis is increased and numerous studies suggest that a high-
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fat diet enhances tumor risk [45].  Altered metabolism is a common feature in many 
cancers involving upregulated glycolysis [46], as well as elevated de novo lipid synthesis 
[47].  High lipogenesis equips cancers with survival advantages.  Rapid cancer cell 
proliferation demands fast synthesis of cell membranes consisting of phospholipids, 
glycolipids, and cholesterol.  Lipids through diet and cell synthesis can also provide a 
means of energy storage and cell signaling.  Many pro-inflammatory and pro-oncogenic 
cytokines, and prostaglandins, are products of lipid metabolism [48].  The inhibition of 
lipogenesis and fatty acid (FA) degradation through beta-oxidation are targets for 
controlling cancer progression [49, 50].  
FASN is a protein containing seven separate enzyme moieties that catalyze FA 
synthesis.  It consists of two identical 272 kD multi-functional polypeptides and is the 
only protein in mammals responsible for de novo lipogenesis.  FASN synthesizes 
palmitic acid by adding acetyl-CoA to malonyl-CoA to extend the FA chain by two 
carbons at a time to make a 16-carbon chain.  Palmitic acid can then be utilized to further 
synthesize stearate and myristate.  The expression level of FASN is found to be elevated 
in multiple cancers including melanoma [51], colorectal cancer [52], and PCa [53].  
FASN is normally expressed at very low levels in the prostate due to high dietary fat 
intake but is up-regulated as early as PIN and is highly elevated in 82% of men with 
localized and metastatic PCa [54].  It has also been reported that an increased copy 
number of the FASN gene is often present in PCa tissue [55] and  several germline SNPs 
of FASN are associated with higher PCa risk [56].  In addition, FASN is a cytoplasmic 
protein in normal cells. However, nuclear localization of FASN is associated with PCa 
progression [57].  In normal tissues, de novo synthesis of FAs through FASN is down-
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regulated by the availability of dietary FAs [58].  Although elevated lipid content in 
tumor tissue was identified 80 years ago [59], the link between dietary and de novo fatty 
acids in PCa is still not clear.  FASN is transcriptionally regulated by SREBP-1 [60], 
which is downstream of PI3K/Akt [61] and androgen/AR [62].  However, FASN 
expression remains elevated in the prostate tumors of men receiving androgen ablation 
therapy [54], indicating a loss of normal regulation of gene expression in cancer.  In one 
PCa study, Nelfinavir, a drug for treatment of AIDs, down regulates FASN expression 
through suppression of the translocation of SREBP-1 [63].  One of our goals is to identify 
novel down-stream target(s) of FASN. 
 
2) FASN expression and activity are associated with cancer progression 
              FASN is a metabolic oncoprotein and is being pursued as a therapeutic target 
[64].  Overexpression of FASN has been observed in many cancers and it promotes 
tumor progression through affecting oncogenic pathways [65, 66].  FASN inhibitors are 
being developed to decipher potential functions of FASN and help understand the 
underlying mechanisms with the ultimate goal of developing novel anti-tumor drugs 
against PCa [67].   
High FASN expression renders cancer cells a greater survival advantage  
High FASN levels have been found to trigger multiple tumorigenic pathways.  
For example, in pancreatic cancer, FASN activates EGFR/ERK pathway [65].  Likewise, 
in colorectal cancer, FASN overexpression increases cellular respiration [68].  Other 
examples include co-overexpression of FASN and phospho-c-met in papillary and 
follicular thyroid carcinomas [66]; and high co-expression of c-Met receptor kinase and 
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FASN in B-cell lymphoma [69].  One study also showed that FASN overexpression 
could induce Wnt1 palmitoylation, elevate Wnt1/beta-catenin signaling and promote 
tumor invasion in mice [70].  It has also been demonstrated that activation of the PI3K-
Akt pathway can increase FASN expression [71], indicating FASN not only regulates 
down-stream oncogenic pathways but also be regulated by up-stream oncogenic 
pathways.  
FASN inhibitors induce cell death and apoptosis 
Previous studies on FASN utilized multiple FASN inhibitors to analyze the 
protein’s function and its roles in pathway networks.  These FASN inhibitors include 
Cerulenin, C75, luteolin, orlistat, TVB-3166, and several others.  Cerulenin is a fungus 
derived natural compound and C75 is one of its synthetic analogs.  Cerulenin and C75 are 
both found to induce apoptosis or suppress cell proliferation in breast cancer [72], 
melanoma [73], colorectal cancer [74], and PCa [75, 76].  Another natural compound, 
luteolin, is mainly derived from leaves of dietary vegetables, such as celery.  As a FASN 
inhibitor, luteolin can inhibit the c-Met pathway [77] and importantly, it was found that 
adding palmitate could restore c-Met levels [37].  In addition, a similar study carried out 
in a breast cancer cell line, demonstrated that osthole, a fruit-derived compound was 
reported to suppress FASN in breast cancer cells overexpressing HER2 [78].  Osthole can 
suppress c-met, which was confirmed with C75 treatment and again c-Met suppression 
can be reversed by palmitate [38].  Another FASN inhibitor orlistat, originally used to 
treat obesity, inhibits proliferation, as well as metastasis in oral squamous cell carcinomas 
[79] and suppresses cell proliferation of PCa cell line PC3 both in vitro and in vivo [80].  
Furthermore, a recent study using a newly developed FASN inhibitor, TVB-3166, 
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showed growth suppression in many cell lines from ovarian, pancreatic, prostate, and 
hematopoietic cancers through multiple pathways including modulating lipid raft 
structure, inhibiting Akt and beta-catenin signaling, as well as the sterol synthesis 
pathway [81].   
 
5 Dietary fatty acid consumption and prostate cancer 
1) Dietary nutrition and prostate cancer 
Epidemiology studies, clinical trials and many in vitro studies have revealed an 
increased risk of developing PCa and a worse prognosis after treatment is associated with 
lifestyle, and the diet is a major part of it.  Many studies employing dietary agents for 
modulation of cancer initiation and progression have been carried out.  For example, 
pomegranate juice was found to inhibit PCa cell growth [82].  One effective component 
of pomegranate juice is ellagic acid (EA), which triggers an apoptosis pathway and 
suppresses cyclin D1 and cdk [83].  A study using a mouse model of PCa indicated that 
curcumin slows down PCa growth, and AR expression is decreased in the curcumin 
treated group [84].  Green tea is also considered to have anti-tumor activity through the 
epigallocatechin gallate (ECGC) component of the tea acting in part via inhibition of 
FASN.  A meta-analysis on low grade PCa showed that tea consumption is protective 
regardless the type of the tea [85].  One study also showed that coffee consumption may 
decrease PCa risk [86], but another study showed that the risk reduction occurs only 
when consuming boiled coffee [87].  Intake of Vitamin C reduces PCa risk [88], Vitamin 
D inhibits PCa proliferation when combined with metformin [89] or Vitamin A [90].  In 
contrast, vitamin K antagonist intake decreases PCa risk [91, 92].  In prostate tumors, the 
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main energy source appears to be through lipid pathways [93], thus FA metabolism may 
play a critical and specific role in PCa progression.   
 
2) An overview of dietary fatty acid 
Daily dietary FA consumption consists of saturated fat and polyunsaturated fatty 
acids (PUFAs).  Most PUFAs consumed can be divided into sub-categories of n-3, n-6 
and n-9 PUFAs based on the position of the first double bond counting from the methyl 
end.  In most cooking oils, oleic acid (OA, C18: 1), which is monounsaturated fatty acid, 
is the major form of dietary n-9 fatty acids.  While mammalian cells can interconvert the 
PUFAs within each of the n-3/6 series, the two series are not interchangeable.  In 
addition, neither n-6 nor n-3 PUFAs can be synthesized de novo in mammals, thus dietary 
intake is critical for daily demands.  The most abundant PUFAs in daily cooking oil are 
n-6 FAs, including linoleic acid (LA) (18:2) and arachidonic acid (AA) (20:4).  Besides 
flaxseed oil (mostly alpha-linolenic acid, ALA, 18:3), n-3 FAs exist in very small 
amounts in other vegetable oils.  One of the important animal sources of FAs is fish oil 
(FO; salmon, mackerel, tuna and other cold water marine fish).  FO contains n-3 PUFAs 
with longer carbon chains than ALA: eicosapentaenoic acid (EPA, 20:5) and 
docosahexaenoic acid (DHA, 22:6).  Compared to saturated FAs, PUFAs are correlated 
with lower risk of cardiovascular disease [94].  However, the ratio of different n-3, n-6 
and n-9 PUFAs consumed will impact health benefits as some PUFAs compete as 
substrates to trigger anti-tumorigenic or pro-tumorigenic pathways [95]. 
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3) Impact of dietary fatty acid on prostate cancer 
The risks and benefits of dietary FA composition, and the ratio of n-3/n-6 PUFAs 
in particular, are considered to be associated with the prevention and control of various 
diseases, especially PCa [95].  Consumption of n-6 PUFAs including LA and AA from 
certain plant oils correlates with increased PCa risk whereas consumption of n-3 FAs 
found in marine fish, EPA and DHA, correlates with decreased risk [96].  
Clinical trials and population studies have been carried out to investigate the 
correlation between different dietary FA consumption and PCa.  A study involving 6,272 
Swedish men found that men who do not eat fish have a much higher frequency of 
developing PCa compared to their fish-consuming counterparts [97].  A recent clinical 
study on low-risk PCa patients receiving a high n-3 PUFA diet intervention found that the 
increase of EPA in prostate tissue decreases the cancer progression risk [98].  
Interestingly, this paper found prostate cancer risk is neither significantly associated with 
EPA intake nor with EPA level in red blood cells [98].  Patients receiving low-fat FO diet 
demonstrated a lower cell cycle progression score and lower 15-Hydroxyicosatetraenoic 
acid (HETE), a pro-inflammatory metabolite [99].  Similarly, a phase-II clinical trial 
showed that patients receiving low fat and low n-6/n-3 PUFA ratio diets have a lower 
cancer progression index compared to the western style diet group [100].  A nested case-
control study of multiple different cancers showed that in patients with a lower intake of 
n-3 PUFA, soluble intercellular adhesion molecule-1 (sICAM-1) levels were associated 
with cancer risk while in patients with a higher n-3 PUFA intake, there is no such 
association [101].  
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Another study on circulating FAs supports the preventive function of n-3 PUFAs 
[102] and in this study they measured erythrocyte n-3 PUFA levels.  However, a 
prospective research study in PCa patients with localized tumors indicated that long chain 
n-3 PUFAs in plasma phospholipid fatty acids were associated with higher PCa risk; and 
to the contrary, n-6 PUFAs were correlated with lower PCa risk [103].  This finding is 
consistent with two other studies, in which n-3 phospholipid in plasma or serum was 
measured [104, 105].  One of the studies found trans-fatty acids were associated with 
lower PCa risk, while DHA was associated with higher high-grade PCa risk [105].  This 
plasma phospholipid study generated controversy and points to a gap in understanding 
the FO mechanism of action, cell lipid uptake, tissue-specific FA concentrations and lipid 
metabolism [106, 107].  All of these factors vary widely from one individual to another 
and the reasons behind the opposing findings on n-3 fatty acids and cancer risk remain 
indeterminate.  
N-3 PUFAs have also been shown to modulate FA synthesis through inhibition of 
the FASN expression [108]. Several studies have shown that n-3 PUFAs suppresses Akt, 
EGF and AR pathways [109-111].  Activation of these pathways can directly or indirectly 
promote changes in FASN levels by activating its transcription factor SREBP-C1.  
In addition to n-3 and n-6 FAs, other FAs such as OA may also play important 
roles in reducing cancer risk.  Unlike n-3 PUFAs, which are derived from limited sources 
(flaxseed, certain fish), n-9 fatty acids (such as OA) are one of the dominant components 
in most daily cooking oil.  Results from studies investigating OA and cancer, however, 
are controversial.  Some studies indicate OA has inhibitory effects on PCa cell 
proliferation [112], while others observed a higher OA/stearic ratio in untreated and more 
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advanced PCa patients [113, 114].  However, whether the high level of OA/stearic ratio is 
due to more endogenous OA production, dietary OA consumption, or the decreased level 
of stearic acid remains to be investigated.  In the present study, we selected OA, a 
commonly consumed FA, as one of the controls to be used in comparison with FO to 
identify the pathways activated or suppressed in PCa cells, specifically by FO. 
Another role of n-3 PUFAs may be in sensitization of PCa, as well as other 
cancers to chemotherapy or other stress-inducing factors.  It is reported that n-3 PUFAs 
restored chemosensitivity of colon cancer cells against multiple drugs [115] and 
mammary tumors against docetaxel [116].  However, there was also a study that showed 
an opposite effect with combination treatment of n-3 PUFA and tamoxifen which 
increased Erk1/2 and Akt phosphorylation and tampered apoptosis induced by tamoxifen 
alone [117].  A study in leukemia cells also showed n-3 PUFAs can activate 
RAS/ERK/C/EBPb pathway through DNA demethylation [118].  Although several large 
studies in patients have reached different conclusions regarding n-3 PUFA intake and 
PCa risk [103, 119], most in vitro and in vivo studies have demonstrated that n-3 PUFA 
exerts inhibitory functions on PCa cells.  For example, EPA was found to inhibit the 
phosphorylation of ERK, FAK, and p70S6K [120] and EPA induced JNK 
phosphorylation and apoptosis [121].  Similarly, it is reported that both n-3 and n-6 
PUFAs suppress JAK1, STAT1, ERK1/2, and JNK phosphorylation induced by IFN-
gamma [122].  Another study also found n-3 PUFAs suppress phosphorylation of Akt but 
have no effect on phospho- or total Erk 1/2 [123].  Additional studies have shown that 
DHA suppressed phosphorylation at AKT (T308) but changed AKT (S473) 
phosphorylated protein localization without affecting its phosphorylation level, as well as 
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regulated Akt’s interaction with BAD [124].  An earlier study indicated the suppression 
of PDK/Akt/Bad is SDC-1 dependent and induced apoptosis [109].  One of the suggested 
causes of changes to signaling molecule function is modulation of phosphorylation by 
disruptions of lipid raft microdomains by n-3 PUFA [125].  Lipid raft microdomains 
harbor numerous signal transduction proteins.  In addition to the classic signaling 
pathways, such as Akt, JNK or Erk, which were studied widely in cancer research, there 
are may be other undiscovered pathways modulated by n-3 PUFA.  The regulation of 
cancer cells by different FAs involves multiple pathways, networks as well as numerous 
proteins and small molecules that impact cell survival, stress response and metabolism.  
 
6 Goal of the study 
As the diet provides daily exposure to FAs, there is an extended capacity to exert 
influence on numerous cellular events including energy storage and breakdown, cell 
membrane structure, subcellular trafficking, and bioactive metabolite synthesis.  Many of 
these pathways can be affected by different FA moieties [126].  To gain a clearer picture 
of the changes induced by FAs, a quantitative proteomics approach may help elucidate 
changes in global protein expression and post-translational modifications. This state-of-
the-art approach has become an effective approach to identify factors involved in FA 
metabolism [127].  
We suggest that the understanding of the regulatory effects of FO discovered from 
previous studies is far from complete.  Our overall hypothesis is that FO exerts anti-
oncogenic functions in prostate cancer cells through altering expression and post-
translational modifications of multiple proteins. Our aim is to better understand the 
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molecular targets and key pathways of FO metabolism.  To achieve this, two large-scale 
proteomic studies were performed, one to assess global protein expression changes and 
the other to delineate global protein phosphorylation changes induced by fatty acid 
treatments. 
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Chapter 2 Dietary fatty acid metabolizing enzymes regulated by FASN 
1 Preliminary data and significance of the study 
  As an oncoprotein, FASN, is a candidate therapeutic target for cancer [64].  To 
investigate how FASN affects PCa cells and identify potential molecular targets of 
FASN, a series of siFASN knockdown experiments were carried out using multiple PCa 
cell lines and microarray analyses.  As shown in Fig. 2-1, the expression levels of several 
genes involved in PUFA metabolism were significantly altered when PPC-1 cells were 
treated with siFASN.  Microarray results from the LNCaP cell line also showed similar 
gene expression patterns. 
Genes affected by FASN knockdown include choline kinase, phospholipase C, Δ-
5 (FADS1) and Δ-6 (FADS2) desaturases, thromboxane A synthase, and 
cyclooxygenase-2 (COX2).  Choline kinase catalyzes the phosphorylation of choline to 
form phosphocholine.  Overexpression of this gene has been demonstrated to confer 
oncogenic properties in kidney cells while high enzyme activity correlates with tumor 
grade in breast carcinoma [128, 129].  In this study, this enzyme is down-regulated. 
Similarly in gene expression profile, phospholipase C, which liberates arachidonic acid 
(AA) from membrane phospholipids, as well as Δ-5 (FADS1) and Δ-6 (FADS2) 
desaturases, which both participate in the metabolism of dietary n-3 and n-6 fatty acids to 
EPA and AA, respectively [130], are down-regulated.  Δ-6 desaturase also plays a role in 
the further metabolism of AA and EPA.  In addition, Δ-9 desaturase was down-regulated 
by FASN depletion and is involved in the conversion of stearic acid to OA [130]. 
Thromboxane A synthase, which is responsible for catalyzing prostaglandin H2 to 
thromboxane A2 [131], was also down-regulated.  Finally, a small degree reduction in 
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COX2 mRNA was induced with FASN knockdown.  In addition to this study, a previous 
immunohistochemistry study showed an over-expression of 15-lipoxygenase-1 (15-
LOX1) in prostate tumor tissue as compared with normal adjacent tissue [132].  
COX and LOX are two families of enzymes that can catalyze reactions between 
PUFAs and oxygen to produce eicosenoids.  COX generates prostanoids and LOX 
generates leukotrienes.  Both the two enzymes have several forms.  Human 15-LOX1 is a 
highly-regulated, tissue- and cell-type-specific lipid-peroxidating enzyme that has several 
functions ranging from physiological membrane remodeling to pathogenesis of 
atherosclerosis, inflammation, and carcinogenesis [133].  15-LOX1 metabolizes LA to 
13(S)-hydroxyoctadecadienoic acid [13-(S)-HODE], which can regulate cell growth, 
differentiation and vascular homeostasis [134-143].  A previous study demonstrated that 
an n-3 diet in a PCa xenograft mouse model decreased serum PSA levels, induced 
apoptosis, and inhibited tumor proliferation [144].  The same study demonstrated that 
EPA competed with LA as a substrate for the lipoxygenase (15-LOX1), resulting in a 
decrease in the pro-tumorigenic metabolite 13(S)-HODE, and an increase in 15-HEPE 
primarily associated with anti-inflammatory and anti-tumorigenic effects.  
In addition to 15-LOX1, evidence also suggests that other metabolic enzymes 
such as COX2 play important roles in PCa pathobiology.  AA also acts as a substrate for 
cyclooxygenases COX1 and COX2.  Most tissues constitutively express low levels of 
COX1 with minimal or no COX2.  Studies support an association between inflammation 
and PCa [145, 146].  Growth factors or inflammatory agents rapidly induce COX2 
expression in the prostate [147] and studies show that COX2 is overexpressed in PCa 
[148-150].  COX2 overexpression, leading to the production of pro-inflammatory PGs 
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(e.g., PGE2), possibly contributes to PCa pathobiology.  EPA also competes with AA for 
COX2 activity [151].  Although the metabolites of PUFAs directly impact PCa through 
both diet and metabolic enzyme expression, the mechanisms of n-3 PUFA action remain 
to be determined.   In this study we sought to find out whether FASN depletion will lead 
to alteration of expression of these enzymes, as microarray data suggested. 
 
2 Materials and methods 
1) Cell culture  
The PCa cell line, PC3 (ATCC), was grown in RPMI-160 medium (HyClone, 
Logan, UT, USA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA), 
100 U/ml penicillin and 100 µg/ml streptomycin (Lonza, Walkersville, MD, USA) in 
37°C with 5% CO2.  For the AR positive PCa cell line, LAPC4, IMDM medium 
(HyClone, Logan, UT, USA) was used.   
2) siRNA transfection 
Cells were plated at 30~60 x104 cells/well in 6-well plates.  Within 24 hrs post-
plating, cells were transfected with synthesized siRNA targeting FASN.  The siRNA-free, 
transfection reagent-only control, and the non-targeting siRNA sequence were used as 
negative controls, referred as control and siNonT, respectively.  Transfection kits were 
purchased from Pharmacon RNAi Technologies (Denver, CO, USA) and the siRNA 
transfection was performed according to the protocol. 
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3) Western blot 
Cell pellets were lysed with NP-40 lysis buffer supplemented with 1% protease 
inhibitor (Thermo-Fisher Scientific, Waltham, MA) and phosphatase inhibitor (Sigma-
Aldrich, St. Louis, MO, USA).  Laemmli buffer (Bio-Rad, Hercules, CA, USA) 
containing 5% 2-mercaptoethonal (Fisher Scientific, Pittsburgh, PA, USA) was added to 
cell lysate supernatant and the mixtures were boiled to denature.  Proteins were separated 
by SDS-PAGE gel then transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA).  
Blocking was done in 5% BSA (Roche, Indianapolis, IN, USA).  PVDF membrane was 
incubated with primary antibodies against COX2 (Cell Signaling Technology, MA, 
USA).  Bands were detected by ECL™ Western Blotting Detection Reagents 
(Amersham™, GE Healthcare, Piscataway, NJ, USA).   
4) Quantitative mRNA measurement 
Cells were harvested and RNA extraction was carried out using RNeasy Plus Mini 
Kit (Qiagen, Valencia, CA, USA).  Reverse transcription was performed using 
QuantiTect Reverse Transcription kit (Qiagen).  Realtime PCR was performed on 
QuantStudio 12K Flex (Applied Biosystems, Foster City, CA, USA) and the protocol was 
designed according to Taqman Gene Expression Assay (Applied Biosystems, Foster City, 
CA, USA).  The gene of interest was labeled with reporter dye FAM and Glucuronidase β 
(GUSB), which serves as internal standard was labeled with reporter dye VIC.  Realtime 
PCR primers and probes targeting FASN (assay ID: Hs01005622_m1), COX2 (assay ID: 
Hs00153133_m1), FADS1 (assay ID: Hs00203685_m1), 15LOX1 (assay ID: 
Hs00993765_g1), SCD (assay ID: Hs01682761_m1), FADS2 (assay ID: 
Hs00188654_m1), TBXAS1 (assay ID: Hs01022706_m1), GUSB (assay ID: 
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Hs00939627_m1), as well as Mastermix (the reaction solution), were designed and 
purchased from Applied Biosystems. 
5) Liquid chromatography/mass spectrometry (LC/MS)-based unbiased global 
proteomic analysis 
The cell pellets were lysed and sonicated in 8M urea.  Bradford assay was carried 
out to determine the total protein concentration.  Chicken lysozyme, which serves as a 
QA/QC reference protein was spiked in every sample to be analyzed (0.6%, w/w).  
Reduction and alkylation were carried out with triethylphophine and iodoethanol at 37 °C.  
The resulting samples were dried overnight in a speed vacuum and re-dissolved in 70 µl 
of 100 mM ammonium bicarbonate (ABC) buffer.  Tryptic digestion was carried out by 
adding trypsin (0.6% of sample protein, w/w) (Worthington, Lakewood, NJ) diluted in 
100 mM ABC buffer and letting the samples to be digested overnight.  All the samples 
were filtered by a 0.45 µm PVDF filter (Emd Millipore Corporation, Billerica, MA) prior 
to each injection.  Duplicate injections were performed for every sample in a randomized 
order for all 36 injections using a 20-µg total protein per injection. The tryptic peptides 
were loaded onto a C18 microbore column (Xbridge 2mm* 50mm, Waters, Milford, MA) 
and eluted with a gradient from 5% to 40% acetonitrile and 0.1% formic acid over 155 
min at a flow rate of 200 µl/min.  Data was acquired on a Thermo-Fisher Scientific linear 
ion-trap (LTQ) mass spectrometer. “Triple-play” mode was applied for data acquisition, 
which consists of MS scan, Zoom scan, and MS/MS scan.  SEQUEST® search engine 
was used for database search against International Protein Index (IPI) database (version 
v3.83).  Mass tolerances of precursor ions and product ions were set at 2.0 amu and 1.0 
amu, respectively. Protein/peptide identification validations were carried out using 
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PeptideProphet/ProteinProphet software developed by Institute of Systems Biology (ISB) 
and available for free downloading.  Label-free protein quantification was performed 
using an in-house developed “ProteinQuantXL” software [152].  A one-way ANOVA 
analysis was performed on the data (n=6) and q-values were calculated. 
6) Pathway and statistical analyses 
The gene ontology networks were extracted using Ingenuity pathway analysis 
software (IPA).  Associated network functions were extracted from differentially 
expressed genes (also known as “focus genes”).  The network generation was carried out 
as follows: 1) according to the ranking of interconnectedness of these genes, top ranked 
genes are selected; 2) The most connected gene is selected and the rest of the focus genes 
are added to this seed gene; 3) If the network still contains less than 35 genes, genes 
outside the focus gene list are added to the network if they are related to the network; 4) 
p-value is defined as the probability of finding numbers of f or more focus genes in the 
network in a randomly selected gene list (e.g., N=35); and 5) Score = -log10 (p-value). A 
lower p-value (= a higher score) indicates a less likelihood that the network extraction is 
random [153].  
Canonical pathway analysis determines the association between proteins of 
interest and certain canonical pathways.  The lower the p-value, the less likely that the 
association is random. It also gives a ratio representing the overlap of the gene list of 
interest and the gene list of certain canonical pathways [154].  
Unpaired t-test analysis was performed using a statistic software Graphpad 6.0.  
q-value was calculated using a web-based tool: q-value estimation for false discovery rate 
(FDR) control (http://qvalue.princeton.edu) 
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3 Results 
1) Validation of candidate target of FASN 
Validation of microarray results by Western Blot was performed using an 
additional siRNA knockdown system (Pharmacon RNA Technologies).  Western blot 
analysis showed that the FASN protein levels were significantly reduced 72 hours post-
transfection (Fig. 2-2 A).  In the FASN activity assay, the pathway activity was reduced 
by approximately 30% over control and non-targeting siRNA treated cells (Fig. 2-2 B).  
The genes for validation were selected from the microarray results and genes known to be 
involved in functional pathways of PUFA processing were examined by Real-time PCR.  
In PC3 cells, COX2 mRNA levels showed a significant decrease (p=0.0009) in the 
siFASN treated group 48 hours post-transfection (Fig. 2-3 A) but after 72 hours, the 
observed mRNA change is not significant (P=0.075) (Fig. 2-3 B).  The COX2 protein 
levels were also decreased in siFASN transfected cells compared to control and non-
targeting siRNA treated cells (Fig. 2-3 E).  In addition to COX2, FADS1 levels were also 
significantly suppressed (p=0.049) 48 hours post-transfection (Fig. 2-3 A); although no 
significant change was observed after 72 hrs (Fig. 2-3 B), 15LOX1 levels appeared to 
have a decreasing trend in expression with FASN siRNA treatment but the effect was not 
found to be significant (Fig. 2-3 B).  Since PC3 is an AR negative PCa cell line and 
represents hormone insensitivity, we also tested FASN knockdown in a PCa cell line with 
wild-type AR, LAPC4 (Fig. 2-3 C).  LAPC4 has very low COX2 mRNA levels 
compared to PC3 (12 cycle difference in Real-time-PCR).  However, COX2 mRNA 
levels were significantly decreased (p=0.002) 72 hours post-transfection rather than 48 
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hours as observed in the PC3 cells (Fig. 2-3 D).  FADS1 and 15LOX1, which decrease 
with FASN knock down in PC3 cells, were not altered in LAPC4.  
2) Proteomics analysis of siFASN knockdown 
To investigate the downstream pathways of FASN, an LC/MS-based label-free 
global protein quantification technology was used to compare the proteomes of PCa cells 
affected by FASN.  1187 proteins were identified with peptide probability over 0.8 and 
protein probability over 0.9.  Probability was generated by protein/peptide identification 
using PeptideProphet/ProteinProphet software.  Among them, 516 (43.5%) showed 
differential expressions among the groups according to ANOVA p ≤ 0.05  (n=6) and q ≤ 
0.05 thresholds.  When comparing siFASN and siNonT groups, 201 out of 516 proteins 
(39.0%) (besides FASN) are found significantly changed (multiple comparison test 
p≤0.05, fold change ≥ |1.2|). 
Noticeably, the fold change of FASN in this proteomic study is smaller than in Q-
PCR and western blots with only 1.6-fold change between the siFASN and the siNonT 
groups and 1.8-fold change compared to control.  However, protein frequency (protein 
frequency=number of injections in which protein X was detected/total injection number) 
for all injections shows that in the siFASN-treated group, the protein frequency is 8.3%, 
comparing to 91.7% in control group and 100% in siNonT group, which indicates a 
substantial knockdown of FASN. 
Ingenuity Pathway Analysis (IPA) was applied to extract biological networks 
from the 201 proteins that were differentially regulated.  Top scored networks [Score = -
log10 (p-value)] were extracted as follows (Table 2-1 A): 1) amino acid metabolism, 
post-translational modification, small molecule biochemistry; 2) hematological disease, 
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organismal injury and abnormalities, cell morphology; 3) cell death and survival, DNA 
replication, recombination, and repair, energy production; 4) cellular movement, cell 
morphology, connective tissue development and function; and 5) carbohydrate 
metabolism, small molecule biochemistry, developmental disorder.  The main molecular 
and cellular functions include: cell death and survival, cellular growth and proliferation, 
nucleic acid metabolism, carbohydrate metabolism, small molecule biochemistry.  Top 
canonical pathways were also generated (Table 2-1 B), they are: gluconeogenesis I, 
glycolysis I, epithelial adherens junction signaling, EIF2 signaling and integrin signaling. 
Among these 201 proteins, 18 proteins have significant (multiple comparison 
P≤0.05) differences between control and siFASN groups.  Control and siNonT groups 
demonstrated the same trend compared to the siFASN group.  Sixteen of the proteins 
were annotated in IPA (Table 2-2).  While a 9-kDa protein encoded by transferrin 
receptor (TFRC) was down-regulated in the siFASN group, the other 15 proteins were 
found to have increased expression levels with FASN knockdown.  The 7 upstream 
regulators of these proteins are: ethionine, indomethacin, lipopolysaccharide CD3, IL1B, 
MYC3, and IL15 (Fig. 2-4).  
 
4 Discussion 
Metabolites of n-6 and n-3 PUFAs directly impact PCa tumor development and 
the ability to do so depends on both diet and the levels of enzymes responsible for 
metabolizing these PUFAs.  A study in liver has shown that the COX inhibitor celecoxib 
can down-regulate FASN independent of COX2 [155], while our results revealed the 
possibility of a reverse regulation: that COX2 can be regulated by FASN.  COX2, being a 
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non-constitutive COX, (also known as prostaglandin-endoperoxide synthase (PTGS)), 
can convert AA to PGE2, an inflammatory molecule, which plays a crucial role in 
prostate inflammation and carcinogenesis.  Both COX2 and FASN were found 
extensively expressed in PCa [55, 156].  The positive correlation between COX2 and 
FASN was also reported in Barrett's esophagus (intestinal metaplasia), which is a risk 
factor for esophageal adenocarcinoma [157].  Both enzymes have been found to be down-
regulated by FO or specific n-3 PUFAs [108, 158].  In a trial in which PCa patients 
received an n-3 rich enriched diet, 4 of 7 patients showed decreasing COX2 mRNA 
expression in prostatic tissue [158].  COX2 expression levels were decreased in the group 
with the lower n-6/n-3 ratio in vivo and in vitro [159].  In addition, inhibitors of FASN or 
COX2 are potent tumor suppressors [76, 160].  COX2 inhibitors have been widely 
studied in the treatment of PCa [161, 162].  The relationship or interactions between 
FASN and COX2 are not well documented.  The results of our study showed that there is 
a possible positive regulation of FASN on COX2.  This might suggest that FASN 
mediates the effects of n-3 or n-6 PUFA on COX2, the increase of which is not only a 
potential trigger, but also one of consequences of PCa progression.  The roles n-6 PUFA 
and COX2 play may vary among different cancer types.  Apart from the mitogenic aspect 
of FASN, our result suggest that the FASN-COX2 pathway might play an important part 
in inflammation at early stage disease and angiogenesis in the later progressive stage.  
The combination of DHA and the COX2 inhibitor celecoxib enhances suppression of 
proliferation and induction of apoptosis in PCa cell lines significantly more than either 
treatment alone [160].  However, some conflicting reports have been published in which 
a phase II low fat/fish oil diet in PCa patients demonstrated that a 4-6 week dietary 
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intervention prior to radical prostatectomy suppressed the tumor cell proliferation without 
changing COX2 or PGE2 levels [100].  
In our current study, we found that in addition to COX2, FADS1 mRNA level 
decreased with FASN knockdown in PC3 cells while FADS2 did not change.  The 
mRNA level of 15LOX1 also showed an insignificant decreasing trend when FASN was 
knocked down.  FADS1 and FADS2 are the enzymes involved in long chain n-6/n-3 
synthesis.  Gene variants of these two enzymes influence PUFA composition in blood 
and breast milk [163], and affect the individual PUFA change in response to FO [164, 
165].  Our results suggest that FADS1 might be affected by the change of FAs synthesis. 
In regards to PCa, however, a recent report showed contradictory results that FADS1 in 
periprostatic adipose tissue was down-regulated in obese/overweight PCa patients [166].  
With respect to the role of 15LOX1, a mouse model demonstrated that 15LOX1-
expressing mice are more likely to have prostatic intraepithelial neoplasia (PIN) [167].  
There is also evidence that the metabolites of DHA under 15LOX1 can act as anti-
proliferation factors [168], illustrating the competitive effects of n-3 over n-6 PUFA for 
15LOX1.  These support the assumption that 15LOX1 might mediate FASN’s effect on 
PCa progression.  Therefore n-3 may function in several ways including decreasing tissue 
concentrations of AA, so there is less available to form n-6 eicosanoids, competing with 
AA for COX and LOX enzymes or potentially counteracting their AA derived 
metabolites. 
Our proteomics study and the follow-up IPA analysis identified an additional 16 
potential targets of FASN.  These proteins are significantly changed under siFASN 
treatment condition when compared to control and siNonTargeting groups, respectively.  
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In the up-regulated proteins identified, annexin-A1 has been reported to play an 
important role in inducing apoptosis of PCa cells [169, 170].  However, expression of 
lysophosphatidylcholine acyltransferase 1 (LPCAT1) was reported to correlate with 
higher risk of PCa [171, 172], as well as TPD52L2，cDNA FLJ53635, highly similar to 
Homo sapiens tumor protein D52-like 2 (TPD52L2), transcript variant 6, mRNA, which 
predicts PCa tumor progression after radical prostatectomy when combined with squalene 
epoxidase (SQLE) [173].  In addition, talin-1 (TLN1), which is expressed at higher levels 
in PCa than in BPH [174]; and S100A11, which also is associated with PCa development 
[175], were both down-regulated with FASN knockdown.  TFRC, which is down-
regulated with siFASN, was reported to be up-regulated under treatment with C75, a 
FASN inhibitor [176].  FASN is a target of n-3 PUFA as well as a regulator of other 
proteins and pathways downstream.  The knockdown of FASN induces alterations in 
multiple downstream targets.  In addition, as shown in results of FASN expression and 
activity, a dramatic decrease in FASN expression does not necessarily lead to complete 
suppression in FASN activity, which is believed to be due to the long half-life of FASN.  
In the proteomic study, it is noticeable in the proteomic study that most changes in 
protein levels are very minor, but statistically significant.  One explanation is that since 
the remaining FASN in the siFASN group still has considerable activity, the impact of 
the depletion of FASN on the biological processes might be limited, especially at a 
protein expression level; another explanation is that altered FASN level and activity 
change protein post-translational modifications.  As a highly expressed oncoprotein, 
FASN has become an attractive therapeutic target and understanding FASN inhibition in 
tumors by n-3 PUFAs provides further insight into the mechanism of PCa initiation and 
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progression.  In addition this study reveals links to how FO impacts the FA molecular 
pathways of PCa.  
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Table 2-1 Network and pathway analysis of differentially expressed proteins in 
FASN depleted PCa cells 
(A) Top associated Network Functions (Score = -log10 (p-value)) 
 
ID Associated Network Functions Score 
1 Amino Acid Metabolism, Post-Translational Modification, Small Molecule Biochemistry 62 
2 Hematological Disease, Organismal Injury and Abnormalities, Cell Morphology 45 
3 Cell Death and Survival, DNA Replication, Recombination, and Repair, Energy Production 41 
4 Cellular Movement, Cell Morphology, Connective Tissue Development and Function 40 
5 Carbohydrate Metabolism, Small Molecule Biochemistry, Developmental Disorder 34 
 
(B) Top Canonical Pathways 
 
Name p-value ratio 
Gluconeogenesis I 4.31E-10 7/47 (0.149) 
Glycolysis I 6.04E-10 7/41 (0.171) 
Epithelial Adherens Junction Signaling 3.04E-07 10/154 (0.065) 
EIF2 Signaling 2.53E-06 10/201 (0.05) 
Integrin Signaling 4.66E-06 10/208 (0.048) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   31 
Table 2-2 Differentially expressed proteins in FASN depleted PC3 cells 
(C: control; F: siFASN; N: siNonT) 
 
Protein 
ID 
Gene 
Name Protein Name 
FC_
F_C 
Multiple_Compari
son_p_F_C 
FC_
N_C 
Multiple_Compari
son_p_N_C 
FC_
N_F 
Multiple_Compari
son_p_N_F 
ANOVA_
p_value 
IPI0000
5859 
KRT7
5 
Keratin, type II 
cytoskeletal 75 1.3 0.004 -1.1 0.2 -1.4 0.004 0.0005 
IPI0001
3895 
S100A
11 
Protein S100-
A11 1.2 0.006 -1.1 0.008 -1.3 0.0001 2.00E-05 
IPI0101
3714 
CAPZ
B 
Capping 
protein (Actin 
filament) 
muscle Z-line, 
beta 1.1 0.006 -1.2 0.003 -1.3 0.0002 1.00E-05 
IPI0094
2539 
ACTN
4 39 kDa protein 1.2 0.01 -1.1 0.03 -1.3 0.003 0.0003 
IPI0000
0816 
YWH
AE 
Isoform 1 of 
14-3-3 protein 
epsilon 1.1 0.01 -1.1 0.1 -1.2 0.007 0.002 
IPI0002
2202 
SLC25
A3 
Isoform A of 
Phosphate 
carrier protein, 
mitochondrial 1.2 0.02 -1.2 0.01 -1.4 0.001 0.0002 
IPI0064
3231 
ANXA
1 Annexin A1 1.2 0.02 -1.2 0.02 -1.4 0.0009 0.0002 
IPI0017
1626 
LPCA
T1 
Lysophosphati
dylcholine 
acyltransferase 
1 1.1 0.02 -1.1 0.02 -1.3 0.0007 0.0001 
IPI0021
5777 
SLC25
A3 
Isoform B of 
Phosphate 
carrier protein, 
mitochondrial 1.1 0.02 -1.2 0.01 -1.3 0.0009 0.0001 
IPI0000
5159 
ACTR
2 
Actin-related 
protein 2 1.1 0.02 -1.1 0.02 -1.2 0.0003 6.00E-05 
IPI0087
8551 P4HB 
cDNA 
FLJ59430, 
highly similar 
to Protein 
disulfide-
isomerase 1.1 0.02 -1.1 0.1 -1.2 0.002 0.0007 
IPI0091
0487 
SERPI
NH1 
cDNA 
FLJ52569, 
highly similar 
to Collagen-
binding protein 
2 1.2 0.02 1 0.7 -1.2 0.03 0.005 
IPI0092
6534 ZYX Protein 1.2 0.02 -1 0.5 -1.2 0.02 0.005 
IPI0092
5162 TFRC 9 kDa protein -1.2 0.02 1.1 0.2 1.3 0.02 0.005 
IPI0074
3469 
TPD52
L2 
cDNA 
FLJ53635, 
highly similar 
to Homo 
sapiens tumor 1.1 0.04 -1.1 0.02 -1.3 0.004 0.0005 
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protein D52-
like 2 
(TPD52L2), 
transcript 
variant 6, 
mRNA 
IPI0029
8994 TLN1 Talin-1 1.2 0.05 -1.1 0.1 -1.3 0.007 0.002 
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Figure 2-1 FASN siRNA alters gene expression of fatty acid pathways. 
A gene array analysis of FASN siRNA treated PPC1 using Affymetrix U131 chip 
identified genes involved in phosphatidylcholine synthesis (choline kinase), arachadonic 
acid liberation (phospholipases) and AA metabolism (Δ5- and Δ6-desaturases), 
prostaglandin synthesis (COX2), Δ9-desaturase was also downregulated by FASN siRNA 
and is involved in the conversion of stearic to oleic acid.  
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   A 
 
 
 
 
   B 
 
                  
 
Figure 2-2 FASN was knocked down by siRNA in PC3 cells. 
A: FASN protein level by Western Blot 72 hours post transfection. B: FASN activity 
level 72 hours post transfection. Labeled fatty acids were obtained by 14C-acetate 
incorporation and Folch extraction. DPM values were measured by scintillation count. 
Fold change was calculated by normalizing results to control group. (unpaired t test 
comparing siFASN and siNonT group, n=3, *: p<0.05) 
 
 
 
 
 
 
 
 
FASN
β-­‐actin
control siFASN siNonT
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Figure 2-3 FASN knockdown changes the expression of PUFA metabolic enzymes. 
A-B: mRNA levels of FASN, CO2, FADS1 and 15LOX1 in PC3 cell were measured by 
realtime-PCR 48 hours and 72 hours post transfection. n=5, C-D: mRNA levels of FASN, 
CO2, FADS1 and 15LOX1 in LAPC4 cell were measured by realtime-PCR 48 hours and 
72 hours post transfection. n=3  E: COX2 protein level by Western Blot 72 hours post 
transfection in PC3 cells. (unpaired t test comparing siFASN and siNonT group, *: 
P<0.05. ** P<0.1) 
 
 
 
 
 
 
control siFASN siNonT
COX2
β-­‐actin
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Figure 2-4 IPA based upstream regulator analysis on 16 proteins differentialy 
expressed in siFASN group compared to control and siNonTargeting group. 
The top 7 upstream-regulators (IL15, IL1B, MYC, CD3, lipopolysaccharide, 
indomethacin and ehionine) shown in the inner circle modulate 12 of these 16 proteins, 
which are shown in outer circle.  Solid line: direct regulation; Dash line: indirect 
regulation. 
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Chapter 3 Global proteome alterations induced by polyunsaturated fatty acids in 
PCa cells 
1 Introduction 
Except for flaxseed oil (alpha-linolenic acid, ALA) and some fish oil (DHA and 
EPA), n-3 PUFA, one of the essential FAs, exist as a very small portion of dietary oil 
intake.  To the contrary, saturated fatty acids, OA, and n-6 PUFAs are main components 
of daily cooking oil, including corn, peanut or sunflower seed oil.  Proteomic studies of 
their effects on human health have been previously carried out [177-183].  However, 
most of these studies used two-dimensional gel electrophoresis approaches with study 
objectives varying from insulin resistance to colon inflammation [177-183].  Large-scale 
proteomic studies on dietary fish oil effects on PCa using the LC/MS/MS based label-free 
protein quantification method has not yet been reported.  
The aim of this study was to better understand the pathways involved in FO 
inhibition of PCa cell viability and to further investigate FO and OA’s effects in global 
protein expression.  We compared global protein expression profiles of PC3 cells treated 
with FO and OA at two different time points.  Protein expression data presented here 
clearly demonstrate that FA-mediated molecular changes are not directly linked to FASN 
activity and the function of FAs may likely be mediated through multiple targets.  
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2 Materials and methods 
1) Cell culture  
The PCa cell line, PC3 (ATCC), was grown in RPMI-160 medium (HyClone, 
Logan, UT, USA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA), 
100 U/ml penicillin and 100 µg/ml streptomycin (Lonza, Walkersville, MD, USA) in 
37°C with 5% CO2.  For the AR positive PCa cell line, LAPC4, IMDM medium 
(HyClone, Logan, UT, USA) was used.   
2) Fatty acid treatment  
FO and OA were purchased from KD Pharma Bexbach GmbH (Bexbach, 
Germany).  FO capsules contained 90% n-3 fatty acid ethyl ester (40% EPA, 40% DHA 
and 10% other n-3 PUFAs).  OA capsules contained 90% oleic acid ethyl ester.  100 mM 
stock was made by dissolving fatty acids (FAs) in ethanol.  When treating the cells, FAs-
ethanol stock solution was mixed into complete medium at a 1:1000 ratio to a final 
concentration of 100 µM, while 0.1% ethanol was used in controls.  For day-6 treatment 
samples, the medium was changed four days after the treatment with a fresh medium 
containing FAs.  To harvest conditioned medium (CM), the growth medium was replace 
with serum-free medium, CM was harvested 24 hrs later and cell debris was removed 
with centrifugation at 1,500 rpm.  CM volume was normalized based on cell count with 
fresh serum-free medium to reach a same volume/cell number ratio among different 
treatments.  
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3) Chloroquine (CQ) treatment  
In autophagy suppression assays, chloroquine diphosphate salt (Sigma-Aldrich, 
St. Louis, MO, USA) was diluted to 8 µM in medium. 
4) MTT and colony formation assay 
Cells were seeded in 96-well plates (1,000 PC3 cells or 6,700 LAPC4 cells per 
well, respectively) and grown in complete medium with different FA treatments.  The 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was carried 
out by incubating cells with MTT (Sigma-Aldrich, St. Louis, MO, USA) for 4 hrs.  
DMSO was used to dissolve the formazan.  Absorbance was measured at 570 nm.   Cells 
were seeded in 6-well plates (1,000 PC3 cells or 3,000 LAPC4 cells per well, 
respectively) and grown in complete medium with different FA treatments.  Colonies 
formed at approximately 1 week for PC3 cells and 1.5 weeks for LAPC4 cells.  Colonies 
were fixed and stained with crystal violet, washed and counted. 
5) Western blot 
Cell pellets were lysed in NP-40 lysis buffer supplemented with 1% protease 
inhibitor (Thermo-Fisher Scientific, Waltham, MA) and phosphatase inhibitor (Sigma-
Aldrich, St. Louis, MO, USA).  Laemmli buffer (Bio-Rad, Hercules, CA, USA) 
containing 5% 2-mercaptoethonal (Fisher Scientific, Pittsburgh, PA, USA) was added to 
cell lysate supernatant and the mixtures were boiled to denature.  Proteins were separated 
by SDS-PAGE gel then transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA).  
Blocking was carried out in 5% BSA (Roche, Indianapolis, IN, USA).  PVDF membrane 
was incubated with primary antibodies anti-MSMP (Abnova, Walnut, CA, USA), anti-
sequestosome-1 (Novus Biologicals, Littleton, CO, USA), anti-beta-actin (Fisher 
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Scientific, Pittsburgh, PA, USA), anti-phospho-PDHA1 (Ser232) (LifeSpan Biosciences, 
Seattle, WA) and anti-alpha-tubulin (Sigma-Aldrich, St. Louis, MO) and secondary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Cell Signaling 
Technology (Danvers, MA, USA) sequentially.  Bands were detected by ECL™ Western 
Blotting Detection Reagents (Amersham™, GE Healthcare, Piscataway, NJ, USA).  
Quantification was carried out using ImageJ, an open source image-processing program. 
6) Quantitative mRNA measurement 
Cells were harvested and RNA extraction was carried out using RNeasy Plus Mini 
Kit (Qiagen, Valencia, CA, USA).  Reverse transcription was performed using 
QuantiTect Reverse Transcription kit (Qiagen).  Realtime PCR was performed on 
QuantStudio 12K Flex (Applied Biosystems, Foster City, CA, USA) and the protocol was 
designed according to Taqman Gene Expression Assay (Applied Biosystems, Foster City, 
CA, USA).  The gene of interest was labeled with reporter dye FAM and Glucuronidase β 
(GUSB), which serves as internal standard and was labeled with reporter dye VIC.  
Realtime PCR primers and probes targeting SQSTM1 (assay ID Hs01061917_g1 and 
GUSB (assay ID: Hs00939627_m1), as well as Mastermix (the reaction solution), were 
designed and purchased from Applied Biosystems. 
7) Fatty acid synthesis activity 
Cells were incubated with complete culture medium with 1 µCi/ml 1,2-14C-acetic 
acid sodium salt (PerkinElmer, Waltham, MA) was added to complete medium and cells 
were incubated for 2 hrs.  The medium was discarded.  For lipid extraction, 0.9 ml 
chloroform/methanol (2:1, v/v) mixture and 0.7 ml 4 mM MgCl2 were added to the cells.  
The mixture was vortexed thoroughly and centrifuged at 10,000 rpm.  The upper aqueous 
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layer was removed and the lipid was maintained in bottom layer, which is the chloroform 
fraction.  Extraction was repeated for 3 times.  Every sample was air dried in fume hood, 
then re-dissolved in 200 µl chloroform and finally transferred to 10 ml scintillation fluid 
Ultima Gold™ F (PerkinElmer, Waltham, MA).  Disintegration Per Minute (DPM) value 
was measured by TRI-CARB 2100TR liquid scintillation analyzer (Packard Instrument 
Company, Kennesaw, GA). 
8) Label-free quantitative global proteomic study 
For global unbiased proteomic analysis, cell pellets were lysed in 8 M urea and 10 
mM dithiothreitol (DTT) and then sonicated on ice.  Protein concentrations were 
measured by BCA protein assay.  Lysates with same amount of proteins were taken from 
each sample and chicken lysozyme was spiked into each sample at a final concentration 
of 0.5% (w/w), serving as a quality assurance (QA)/quality control (QC) reference.  
Reduction/alkylation of cysteine residues was carried out by incubating the cell extracts 
with acetonitrile (ACN)/iodoethanol/triethylphosphine (195:4:1, v/v/v) mixture.  Samples 
were dried in a speed vacuum concentrator (Genevac, NY, USA) and resuspended in 310 
µl of 100 mM ammonium bicarbonate, followed by overnight trypsin (Worthington, 
Lakewood, NJ) digestion (trypsin:protein=1:25).  Desalting was carried out by repeating 
ACN-H2O with 0.1% formic acid wash in Silica C18 MacroSpin Column (The Nest 
Group, Southborough, MA, USA).  The resulting peptides were eluted by 80% ACN in 
last step and speed-vac dried.  Samples were resuspended in 5% ACN in water with 0.1% 
formic acid and filtered through Ultrafree-MC Centrifugal filters (EMD Millipore, 
Billerica, MA).  Peptides were eluted with a linear gradient from 5% to 80% ACN 
developed over 120 min at a flow rate of 50 µl/min, and effluent was electro-sprayed into 
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the LTQ Orbitrap Velos Pro mass spectrometer (Thermo-Fisher Scientific, Waltham, 
MA, USA).  Each sample was analyzed by two injections and total injections were 
carried out in a randomly arranged sequence.  X!tandem algorithms were applied to 
search the acquired data against UniProt human database (released in April 2013).  Mass 
tolerance of precursor ion and product ion were 10 ppm and ± 1.0 Da, respectively.  
Peptides and proteins were validated using PeptideProphet and ProteinProphet in the 
Trans-Proteomics Pipeline (TPP, v.4.6).  All the proteins listed in this study have protein 
probability >90% and peptide probability >80%.  Label-free quantification was carried 
out using IdentiQuantXLTM [152].   
9) Multi-Reaction-Monitoring (MRM) experiment 
Sample preparation, including cell lysis, reduction/alkylation and digestion was 
carried out the same way as that in proteomic discovery.  Mass spectrometric analyses 
were performed on an AB/SCIEX 4000 Qtrap mass spectrometer (Sciex, Framingham, 
MA, USA) interfaced with a Dionex U-3000 UHPLC system (Thermo-Fisher Scientific, 
Waltham, MA, USA).  Peptides were injected on an ODS-100V C18 column (1.0mm x 
150mm, Tosoh Biosciences, South San Francisco, CA, USA) and eluted with a linear 
gradient from 5 to 80% acetonitrile over 32 min at a flow rate of 50 µl/min.  The 
parameters were as follows: curtain gas of 40.0 psi, collision gas of 7 psi, ion spray 
voltage of 5500 V, temperature set at 500 oC, ion source gas 1 of 50.0 psi, ion source gas 
2 of 40.0 psi.  Entrance potential is set on 10.0 V; collision cell exit potential is 12.0 V.  
Data acquisition was carried out using the AB/SCIEX Analyst® software.  For MRM 
development, the Skyline software was first used to generate candidate peptides and 
theoretical transitions for each peptide.  PC3 cell lysate was tested to select the best 
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experimental peptide and transitions, which could be stably detected and also had high 
peak intensity.  One specific transition was monitored for each target peptide, which 
represents one specific protein.  Each monitored transition was confirmed by spiking in 
varied concentration of the corresponding synthetic peptides (Fig. 3-1 & Fig. 3-2).  For 
FSCN1, a transition for target peptide 23YLTAEAFGFK32 was monitored: m/z 573.8 
(M+2H+) → m/z 870.4.  For ITGB, a transition for target peptide 182IGFGSFVEK190 was 
monitored: m/z 492.3 (M+2H+) → m/z 666.3.  For CANX, a transition for target peptide 
78GTLSGWILSK87 was monitored: m/z 531.3 (M+2H+) → m/z 790.4.  For MSMP, a 
transition for target peptide 52YFTLGESWLR61 was monitored: m/z 636.3 (M+2H+) → 
m/z 747.4.  For SCP2, a transition for target peptide 48IGGIFAFK55 was monitored: m/z 
426.8 (M+2H+) → m/z 739.4.  A transition for chicken lysozyme, which serves as 
external standard, target peptide 40GYSLGNWVCAAK61 was monitored: m/z 656.8 
(M+2H+) → m/z 892.4.  We also monitored a transition for RPL6, which serves as the 
internal standard, target peptide: 211HLTDAYFK218, m/z 497.8 (M+2H+) → m/z 744.4.  
Declustering potential (DP) and collision energy (CE) were optimized for each peptide.  
Scan time for each peptide was 120 msec and total scan time was 0.875 sec.  
Quantification of target peptide was performed using Skyline software to calculate area 
under curve (AUC) of extracted ion chromatograms. 
10) Proteolytic activity measurement by DQ-BSA 
PC3 cells were plated on 40 mm diameter glass bottom plates at a density of 
40,000 cells/dish.  Twenty-four hours post treatment of FAs, DQ-BSA was added to 
medium reaching a final concentration of 10 µg/ml.  After 1 hour of incubation, the 
medium was changed to regular FAs containing but DQ-BSA free complete medium.  
	   44 
After another 2 hours incubation, cells were washed by PBS and fixed in 2% PFA for 10 
min.  Cell images were captured using ZEISS fluorescent microscope through 
AxioVision Rel 4.8 software.  Laser in Channel of Rhodamine was used to excite 
BODIPY® dye to emit red fluorescence.  
11) Biostatistic and bioinformatic analyses 
The gene ontology networks were extracted using Ingenuity pathway analysis 
(IPA) (refer to Chapter 2-2-5)).  Basic statistics (t-test, ANOVA and q-value) analyses 
were performed using Graphpad 6.0, Excel and R based q-value analysis website 
(http://qvalue.princeton.edu).  Principle component analysis (PCA) was performed on the 
raw data set of protein abundance and a biplot was generated to show abundance 
variations and outliers if there are any [184].  PCA was performed using XLSTAT in 
Excel [185].  
 
3 Results: 
1) FO, not OA inhibits PCa cell growth 
A MTT cell viability assay was performed to assess cell metabolic activity upon 
PUFA treatment.  Shown in Fig. 3-3 A, FO, not OA, suppresses cell viability.  A 
significant difference in cell growth (FO=74.8%C, p=0.0105) was observed after 24 
hours in the FO treated cells but not in OA group (OA=101.4%C, p=0.5493).  This 
observation was confirmed by clonogenic assays, in which colony density was 
significantly lower with FO treatment (Fig. 3-3 B). FO treatment demonstrated 
significant inhibition of colony formation (p<0.05) with no LAPC4 colonies observed in 
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FO treated group after 1.5 weeks.  Again, the OA group showed no significant change as 
compared to control group (p=0.2842).  During colony formation, vacuoles were 
observed in the FO treated cells, which remained single cells and stopped proliferating 
(Fig. 3-3 C). Clonogenic cell survival assays were also performed on androgen receptor 
(AR) positive LAPC4 cells.  Potent inhibition of colony formation by FO was also 
observed in the LAPC4 cells (Fig. 3-3 D).   
2) Both FO and OA inhibit FA synthesis and OA is a more potent inhibitor than FO 
De novo FA synthesis was measured in the FO and OA treated groups after three 
days and six days treatment.  At day three there was no change in fatty acid synthesis 
with fish oil treatment (Fig. 3-4 A), while a 30.97% (p=0.0001) suppression was 
observed in the OA group.  After six days of treatment, a significant suppression of FA 
synthesis was observed in both FO (27.11%, p<0.05) and OA (49.21%, p<0.0001) groups 
(Fig. 3-4 B).  Additionally, OA’s FA synthesis level was lower than with FO treatment 
(OA=69.7%FO, p=0.0301), which suggests that OA is a more potent FA synthesis 
inhibitor than FO.  This observation also implicates that the viability inhibition effect of 
FO on PC3 cells may not be directly linked to FA synthesis. 
3) The differential proteome profile in prostate cancer cells treated with FO or OA 
LC-MS-based label-free protein quantification was performed to investigate the 
longitudinal regulation of FO and OA on PCa cells.  PC3 cells were plated at ~170,000 
cells/plate on 100-mm plates with the complete medium with 0.1% ethanol, 100 µM FO, 
or 100 µM OA, respectively.  Cells were harvested on day 1 and day 6 after treatment for 
MS analysis.  A total of 1,478 proteins were identified with protein probability >99.8% 
and peptide probability >80%.  Protein and peptide probabilities were produced through 
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calculation by TPP.  Random sequences were set up serving as decoy sequences. A 
protein identification probability >99.8% corresponds to a FDR of <1%, which is a 
commonly used cutoff in the proteomics field.   
Protein expression comparison was conducted based on treatment conditions 
(control, FO, and OA) and time-course (day-1 and day-6).  Three hundred and twelve 
proteins were positively identified based on p-values less than 0.05.  As indicated in the 
Table 3-1, majority of the technical variations are under 10% with a few outliers based 
on the internal control (chicken lysozyme) data and the overall %CV is below 13% 
(Table 3-1).  This is what we expected from this type of global protein profiling 
experiment with the platform we applied.  The data was further filtered by FDR-adjusted 
p value (q value cut off=0.05) and the expression levels of 127 proteins were significantly 
changed upon treatment (Table 3-2).  Principal component analysis (PCA) was 
performed on this 127-protein dataset that consisted of 6 treatment groups with 5 
replicates in each group.  Prolonged FO treated group (FO-6 day) was a distinct group 
indicated by the red circle, separated from the other treatments (Fig. 3-5 A).  The blue 
and yellow circles indicate there were fewer protein changes among treatments in day-1 
and between control and OA group in day-6.  By comparing each FO or OA group to its 
same-day corresponding control group, 73 proteins showed significant changes (p≤0.05).  
Log2(Ratio<FO/C>) and  Log2(Ratio<OA/C>) values of protein entries were clustered by 
one minus Pearson Correlation (Gene E online analysis platform, 
http://www.broadinstitute.org/cancer/software/GENE-E/).  Three major clusters were 
generated (shown in Fig. 3-5 B).  Cluster A contained 7 proteins (encoded by 6 genes) 
(Table 3-3), including SCP2 and acyl-coenzyme A oxidase which participate in fatty acid 
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transport and metabolism [186, 187]; coactosin-like protein is reported to be involved in 
PUFA metabolism [188].  Cluster B showed that five of the six proteins (encoded by 4 
genes) were significantly elevated in the FO group one day after treatment, and protein 
expression levels were higher than the OA group.  Among these proteins, sequestosome-1 
(SQSTM1) and heat shock 70 kDa protein 1A/1B (HSPA1A) were identified and have 
roles in the autophagy process [189, 190].  In cluster C, which consisted of 60 protein 
entries, no significant changes were observed in FO and OA groups in the first day of 
treatment.  However, on day-6, FO-treated and OA-treated groups showed divergent 
protein expression changes.  In the FO-treated group, 53 out of 60 proteins showed a 
significant decrease in expression while in the OA-treated group, the majority of 
differentially regulated proteins were elevated and eight of the changes were significant.  
Ingenuity® pathway analysis (IPA) indicated that cell movement, growth and 
proliferation, cell development, cell death/survival, and carbohydrate metabolism were 
the most significant molecular and cellular functions involved (Table 3-4), while 
glycolysis and gluconeogenesis were the top canonical pathways.  Four enzymes from 
cluster C: phosphoglycerate kinase 1 (PGK1), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), pyruvate kinase isozymes M1/M2 (PKM) and its isoform M1 
(PK) and glucose-6-phosphate isomerase (GPI) were all significantly decreased in 
expression in FO-6-day treated group, but have little change in the OA-6-day treated 
group (Fig. 3-6).  
In combination with IPA, the proteins with significant expression changes were 
selected based on the following criteria: 1) protein probability >99.8%; 2) two or more 
unique peptide sequences identified with high confidence; 3) within every group, 
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ANOVA p-value ≤ 0.05, q-value ≤ 0.05; 4) multiple comparison test p-value ≤ 5/ Ntotal 
tests-; 5) protein frequency (occurrence in all injections) >50%; 6) association with cancer, 
prostate, or lipid processing; 7) absolute fold change >1.3.  Under these stringent criteria, 
we identified only one differentially regulated protein, SQSTM-1, in the day-1 treatment 
group.  SQSTM-1 was elevated (1.7-1.8 fold) in the FO group compared to control and 
OA group.  In the 6-day treatment comparison, the expression levels of 4 proteins were 
significantly altered as compared to the controls (Table 3-5).  
4) Key differentially expressed protein validation 
Both Western blot and MRM-based methods were used for validation studies to 
confirm the differential protein expression observed in the global discovery study.  Since 
the majority of these proteins were in the day-6 treatment group, we used an independent 
set of day-6 samples for validation studies.  In MRM, for each selected protein, one 
unique peptide and one pair of precursor and product ions (MRM transitions) were 
selected.  Relative quantity and specificity of these MRM peptides/transitions are 
illustrated in Fig. 3-1 and 3-2.  Synthetic standard peptides were first tested to confirm 
the transition ion pairs derived from Skyline.  Results showed that among the 4 proteins 
changed in the day-6 treatment group, prostate-associated microseminoprotein (MSMP) 
was found significantly decreased when the FO treatment group was compared to control 
(63.3% lower expression in the FO group, p=0.0242).  Down-regulation of MSMP in the 
OA treated group was not significant (28.4% lower expression, p= 0.3474), (Fig. 3-7 A).  
Since MSMP is also a secreted protein, we tested expression in CM of PC3 cell grown in 
the presence of FO, OA or vehicle.  Western blot results show that secreted MSMP in 
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CM appears as a single band around 16kD.  FO treated PC3 cells secreted less MSMP 
compared to control (p=0.0096) or OA group (p=0.029) (Fig. 3-8 F & G). 
The other protein, sterol carrier protein 2 (SCP2), was also found to be 
significantly up-regulated in the FO treated group compared to control (47.1% over-
expressed in FO group, p=0.001), or OA (27.8%FO, p= 0.0113) (Fig. 3-7 B).  However, 
unlike the global proteome results, there was no significant change between OA and C.  
No significant changes were observed in spiked-in chicken lysozyme and RPL6, which 
served as QA/QC samples (constant amount among three groups observed) (Fig. 3-7 C & 
D). 
SQSTM1, a protein involved in autophagy, was found to be over-expressed in FO 
group one day after the treatment in our global proteomic study.  Western blot results 
were consistent with the LC/MS results that demonstrated SQSTM1 levels in the FO 
group were 2.1-fold higher than that in the control group (p=0.042) (Fig. 3-8 A & B).  
Although the proteomic analysis also showed a higher level of expression in FO group 
when FO and OA groups were compared (fold-change=2.35), the change, however, was 
not statistically significant (p=0.0867) based on our p=0.05 cutoff.  There was no 
significant difference between OA and control.  Real-time PCR results showed that at the 
transcriptional level, mRNA expression of SQSTM1 in FO treated group was higher than 
both control (fold-change=2.16, p=0.003) and OA treated group (fold-change=2.26, 
p=0.003) (Fig. 3-8 C).  To further investigate the function of autophagy, autophagy 
inhibitor chloroquine (CQ) was applied to cells with different FA treatment, and LC3 I/II 
levels were measured by Western blot.  The results indicated that, under the condition of 
autophagy suppression induced by CQ, LC3 II levels accumulated significantly (two-way 
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ANOVA, p=0.0005) while LC3 I levels were not affected.  However, no significant LC3 
II changes were observed among FA treatment groups (two-way ANOVA, p=0.7853) 
(Fig. 3-8 D & E), suggesting that autophagy may not be significantly inhibited under this 
experimental condition. 
5) MSMP expression through cell lines 
MSMP expression level was examined in both cell lysates and conditioned media 
(CM) from other prostate cancer cell lines LNCaP, PPC1, LAPC4, C4-2, DU145 and 
human embryonic kidney cell line HEK293, and also cell lysates from normal prostate 
epithelial cell line RWPE1.  PC3 cell line was used as positive control (Fig. 3-9).  Our 
results show that among these cell lines, strong MSMP expression can only be detected in 
PC3 and PPC1, which is considered to be a sub-cell line of PC3.  Also a molecular 
weight difference can be observed that MSMP in cell lysate is smaller compared to its 
secreted counterpart.  The slight difference might be caused by the signal peptides direct 
secreted MSMP to be transported outside the cell membrane. 
6) Proteasomal proteolysis activity under different FA treatment 
Our study has shown that FO could upregulate SQSTM1, which is required by 
autophagy.  Although the upregulation starts from the transcriptional level, we are still 
curious if the degradation process is also affected by FO or not.  The DQ-BSA assay was 
then performed to test whether FO can regulate proteasomal proteolysis activity.  When 
cells intake and digest DQ-BSA into smaller pieces, the self-quench effect of DQ-BSA is 
stopped and under excitation light (the same wavelength to detect Rhodamine Red dye), 
red dots in cells are evident. Fig.  3-10 shows that most cells in all treatments have 
intracellular red dots, suggesting FO may not change the proteasomal proteolysis activity. 
	   51 
4 Discussion 
In this study, we investigated the different molecular pathways of OA and FO 
action in PCa cells.  Previous investigations of n-3 PUFAs and PCa have pointed to some 
of the potential mechanisms of FO on PCa growth inhibition.  One study detected down-
regulated AR protein expression in LNCaP cells after 10 weeks continuous 20 µM DHA 
treatment [123], while another study did not detect a AR protein change in LNCaP cells 
treated by DHA at concentrations as high as 180 µM for 24 to 36 hrs [191], suggesting 
differential regulatory changes over time may have occurred during the treatment periods.  
One point worth noting is that the concentration of the fatty acids used for this study is 
based on our preliminary experiments and other reported studies [192-194].  At 100 µM, 
FASN activity is significantly reduced by OA while cell viability remains unaffected.  
However, in vivo human exposure to this concentration of FAs may never reach 100 µM 
due to its poor water solubility and lipid uptake limitations.  Thus the actual exposure of 
the cells to FAs may be much lower than the calculated 100 µM concentration. 
Our results suggest that only FO, not OA, suppresses PC3 cell viability, and this 
inhibition occurred as early as one day after the treatment.  Hierarchy analysis of global 
proteomic data generated a group of proteins in which the majority of proteins were 
increased after 24-hr FO treatment.  Specifically, both SQSTM1, and shock 70 kDa 
proteins A1A/A1B are connected to autophagy [189, 190] and both were significantly 
elevated one day after FO treatment but with no change in the OA treated group.  This 
result indicates FO, not OA, triggers rapid stress-responding reactions, which may 
explain the early event of inhibition of viability.  The elevated expression of SQSTM1, an 
autophagy associated protein, was also validated by Western Blot (Fig. 3-8A & B).  
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Autophagy activation is critical for rapid proliferating tumor cells in response to cellular 
stress and high metabolic demands.  In the dynamic process of autophagy, SQSTM1 is 
required for the degradation of polyubiquitinated substrates, and SQSTM1 itself is also 
degraded during this process.  The accumulating SQSTM1 level implicates a possible 
inhibition of autophagy, which in turn causes the accumulation of SQSTM1 that should 
be otherwise degraded in a normal autophagy process, suppressing the growth of the 
tumor cells.  Consistent with our result, one study also found elevated SQSTM1 12-hr 
after the treatment of EPA in promyelocytic cells [195].  Conversely, Shin et al. showed 
that autophagy, in this case acting as a tumor suppressor, was activated by DHA and 
played a critical role in apoptosis of PC3 cells induced by DHA [196].  However, in 
investigating the cause of SQSTM1 elevation under FO treatment, we found this 
increased protein expression was most likely regulated by transcriptional mechanism 
rather than reduced post-translational degradation, implicating other transcription 
regulator(s) may be involved.  It has been previously reported that oxidative stress can 
induce SQSTM1 at the transcriptional level, and SQSTM1 triggers antioxidant effects 
[49].  Since FO was found to induce oxidation stress and cytotoxicity [50], we suggest 
that the observed increase of SQSTM1 might take place at the stage when cells are 
starting to respond to oxidative stress.  
Our study suggests that although OA suppressed FA synthesis rate to near 50% on 
day 6, FASN protein level showed no significant change in the OA group compared to 
control.  One study in C6 glioma cells suggested OA was a stronger inhibitor than n-3 
PUFA and other FAs in FA synthesis [197].  Consistent with their results and another 
study in 1999 [198], we found no protein level changes in FASN expression.  
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Interestingly, they discovered that OA down-regulated the expression of another key 
enzyme in FA synthesis, acetyl-coenzyme A carboxylase, which is involved in the 
formation of malonyl-CoA.  In contrast, FASN expression levels in FO treated group are 
decreased compared to OA group (t-test, p=0.05, multiple comparison test p=0.1), 
indicating additional transcriptional level modulation of FASN was triggered by FO.  
Our quantitative global proteomic study also revealed that a group of 
glycolysis/gluconeogenesis enzymes were changed in FO treated cells and four of the 
enzymes were significantly down-regulated in the 6-day treatment group.  Although most 
of the decreased enzymes are shared by both glycolysis and gluconeogenesis, PKM 
specifically catalyzes a rate-limiting step in glycolysis.  In PCa, glucose is not a major 
bioenergy source as in many other cancer types [93], therefore rendering FDG-PET 
imaging ineffective for PCa tumor imaging [199].  However, a study based on NIH 
dbEST database showed PCa tissue has 9 out of 10 glycolysis genes overexpressed 
compared to normal tissue [54].  Additionally, some glycolytic enzymes, PKM and 
PGAM1, are expressed differently between PCa and normal tissue by isoform or post-
translational modification (PTM) level [200].  PCa cell sensitivity to stress is enhanced 
when glycolysis is suppressed [201].  This suggests glycolysis still plays a role in PCa 
even though the glucose uptake is low.  Expression of hepatic pyruvate kinase [202] and 
glucose-6-phosphate dehydrogenase [203] were also reportedly blocked by n-6 or n-3 
PUFAs.  One of the possible mechanisms is through prevention of chREBP translocating 
to nuclei [204].  In the context of cancer cells, the inhibition may be mediated by liver 
kinase B1 (LKB) [205].  Effects of PUFAs on glycolysis are tissue specific so that in 
skeletal muscle cells, the process is reversed [193].  Our study indicates FO may suppress 
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glycolysis by inhibition of expression of multiple enzymes, suggesting that in the PC3 
cell line, decreases in de novo FA synthesis in later time points may be due to lower 
levels of pyruvate supplied by glycolysis.  To the contrary, prolonged OA treatment does 
not suppress glycolytic enzyme expression and we therefore conclude that FO and OA 
may inhibit FA synthesis through different pathways, which are dependent or 
independent of glycolysis down-regulation, respectively.   
In addition to involvement of glycolytic enzymes, additional potential targets of 
FO were investigated and validated in independent sets of samples. Among the five 
candidate proteins in the 6-day treatment arm, the increase of SCP2 and decrease of 
MSMP was validated by MRM.  In the global study, SCP2 was elevated in both FO and 
OA, with the FO group demonstrating significantly higher expression than OA and 
control samples.  This result was confirmed by Western Blot analysis, although the SCP2 
increase in OA group was not found to be significant.  Functionally it is expected that this 
lipid carrier protein expression would increase when exogenous FAs are added to the 
medium.  The other protein, consistent in validation experiments, MSMP, is a highly 
conserved protein and belongs to beta-microseminoprotein family and its expression was 
observed in both benign and tumor tissues.  The immunohistochemical analysis also 
demonstrated that tumor MSMP expression is different from the pattern in benign tissue 
[206].  As a recently identified protein, MSMP has not been well studied. One report 
suggested MSMP has a role in inflammation as a ligand binding to CC chemokine 
receptor 2B (CCR2B) and acts as a chemoattractant.  MSMP binding therefore induces 
the migration of peripheral blood monocytes (PBM) and peripheral blood lymphocyte 
(PBL) cells but not polymorphonuclear neutrophils (PMN) cells [207], indicating a pro-
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inflammation role of MSMP.  MSMP was also found to stimulate p-ERK, which plays a 
central signaling role in cancer progression [207, 208].  Our results demonstrate that FO 
can lower MSMP levels, offering an additional explanation for the anti-inflammation 
action of n-3 FAs in prostate cancer.  Taken together, FO and OA both suppress FA 
synthesis activity but only FO inhibits cell survival.  The global proteomic studies and 
follow-up validation demonstrated that FO modulates protein levels of SQSTM1, MSMP, 
and SCP2 in PCa cells, suggesting a possible longitudinal regulation by FO: inducing 
cytotoxicity after short treatment; suppressing inflammation pathways and inhibiting the 
glycolytic pathway with prolonged treatment. 
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Table 3-1 Chicken lysozyme is used as an external quality control/quality assurance 
protein in label-free quantifications. 
CV (%) of the double injection of each sample, as well as CV (%) of 5 samples X 2 
injections in each treatment groups is shown. 
 
CV (%) between injections in individual sample 
   
CN12A CN12B CN13A CN13B CN14A CN14B CN15A 
CN15
B CN16A CN16B 
8.51282325 
  
11.09747533 
  
0.647072068 
  
2.995175413 
  
2.934507782 
  
CN62A CN62B CN63A CN63B CN64A CN64B CN65A 
CN65
B CN66A CN66B 
3.785901709 
  
23.73699549 
  
0.641360163 
  
0.218983012 
  
1.565582643 
  
TA11A TA11B TA13A TA13B TA14A TA14B TA15A 
TA15
B TA16A TA16B 
8.216934671 
  
6.499618397 
  
0.840747928 
  
3.146318445 
  
4.509634082 
  
TA62A TA62B TA63A TA63B TA64A TA64B TA65A 
TA65
B TA66A TA66B 
3.660808264 
  
7.033933843 
  
2.608942409 
  
0.8545686 
  
0.382488038 
  
TF12A TF12B TF13A TF13B TF14A TF14B TF15A 
TF15
B TF16A TF16B 
14.77135129 
  
10.40685476 
  
0.888087107 
  
0.141211279 
  
0.039087138 
  
TF61A TF61B TF62A TF62B TF64A TF64B TF65A 
TF65
B TF66A TF66B 
12.99787707 
  
3.926032974 
  
5.949187586 
  
2.595616316 
  
2.62955399 
  
CV (%) among injections in every sample 
CV(%)_C
N1 
CV(%)_
CN6 
CV(%)_T
A1 
CV(%)_T
A6 
CV(%)_TF
1 
CV(%)_
TF6 
    9.5 11 12.7 4.9 8.5 4.9 
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Table 3-2 Label-free quantification information for the 127 significantly changed 
proteins. 
Label-free quantification information for the 127 significantly changed proteins.  
CN=control; TF=FO treated; TA=OA treated; FC=Fold change. 
 
Protein 
ID 
Gene 
Name 
Protein Name FC_T
A1_C
N1 
FC_T
F1_C
N1 
FC_T
F1_T
A1 
FC_T
A6_C
N6 
FC_T
F6_C
N6 
FC_T
F6_T
A6 
ANO
VA 
p-
value 
q-
valu
e  
Q1L6U
9 
MSMP Prostate-
associated 
microseminopr
otein 
-1.1 1 1.1 -1 -2 -2 1.80E
-08 
2.12
E-05 
Q00796 SORD Sorbitol 
dehydrogenase 
-1.1 1.1 1.1 1.1 1.5 1.4 1.97E
-07 
1.16
E-04 
Q96EP5
-2 
DAZA
P 
Isoform 2 of 
DAZ-
associated 
protein 1 
1 1 -1 -1 -1 -1 4.40E
-07 
1.73
E-04 
E7EMC
7 
SQST
M1 
Sequestosome-
1 
-1 1.7 1.8 1.1 1.2 1 1.10E
-06 
3.23
E-04 
K7ELW
0 
PARK
7 
Protein DJ-1 -1 -1 -1 1.1 -1.1 -1.2 2.41E
-06 
5.27
E-04 
P62937 PPIA Peptidyl-prolyl 
cis-trans 
isomerase A 
-1 -1 -1 1.1 -1.2 -1.2 2.98E
-06 
5.27
E-04 
B4DQR
8 
ZYX Zyxin -1.1 -1.1 -1 1.2 -1.3 -1.5 3.13E
-06 
5.27
E-04 
Q13501
-2 
SQST
M 
Isoform 2 of 
Sequestosome-
1 
-1 1.6 1.6 1.1 1.1 1 4.12E
-06 
6.06
E-04 
Q99497 PARK
7 
Protein DJ-1 -1 -1 -1 1 -1.2 -1.2 5.78E
-06 
7.10
E-04 
J3QSB5 RPL36 60S ribosomal 
protein L36 
-1 -1 -1 1.1 -1.3 -1.5 6.03E
-06 
7.10
E-04 
P14866-
2 
HNRN
P 
Isoform 2 of 
Heterogeneous 
nuclear 
ribonucleoprot
ein L 
-1 -1 -1 1.1 -1.2 -1.4 1.47E
-05 
1.57
E-03 
Q6IBS0 TWF2 Twinfilin-2 -1 -1.1 -1.1 1.1 -1.3 -1.4 2.26E
-05 
2.19
E-03 
B4E0P1 PSMB
7 
Proteasome 
(Prosome, 
macropain) 
subunit, beta 
type, 7, 
isoform 
CRA_b 
-1.2 -1.1 1.1 1 -1.3 -1.3 2.46E
-05 
2.19
E-03 
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Q96AB
3-2 
ISOC Isoform 2 of 
Isochorismatas
e domain-
containing 
protein 2, 
mitochondrial 
-1.1 -1.2 -1.1 1.1 -1.3 -1.4 2.60E
-05 
2.19
E-03 
D6RG1
5 
TWF2 Twinfilin-2 -1 -1.1 -1.1 1.1 -1.4 -1.5 4.15E
-05 
3.26
E-03 
E9PEP6 NRP1 Neuropilin-1 -1 1 1.1 1.2 -1.2 -1.4 5.48E
-05 
3.43
E-03 
Q13509 TUBB
3 
Tubulin beta-3 
chain 
1 -1 -1.1 1.1 -1.2 -1.3 5.60E
-05 
3.43
E-03 
Q99436 PSMB
7 
Proteasome 
subunit beta 
type-7 
-1.1 -1.1 1 1 -1.2 -1.3 5.84E
-05 
3.43
E-03 
G3V1X
9 
CBX5 Chromobox 
homolog 5 
(HP1 alpha 
homolog, 
Drosophila), 
isoform 
CRA_a 
1 -1.1 -1.1 -1.1 -1.3 -1.2 6.06E
-05 
3.43
E-03 
P14174 MIF Macrophage 
migration 
inhibitory 
factor 
-1 -1.1 -1.1 1.1 -1.5 -1.6 6.15E
-05 
3.43
E-03 
H3BT58 COTL
1 
Coactosin-like 
protein 
1 1.1 1 1.1 1.2 1.1 6.32E
-05 
3.43
E-03 
P33993-
3 
MCM Isoform 3 of 
DNA 
replication 
licensing 
factor MCM7 
1 1 -1 -1 -1 -1 6.94E
-05 
3.43
E-03 
P06744 GPI Glucose-6-
phosphate 
isomerase 
1 1 1 1.1 -1.2 -1.2 7.22E
-05 
3.43
E-03 
Q15067
-3 
ACOX Isoform 3 of 
Peroxisomal 
acyl-coenzyme 
A oxidase 1 
-1.2 1.2 1.5 1.1 1.5 1.3 7.29E
-05 
3.43
E-03 
P14618 PKM Pyruvate 
kinase 
isozymes 
M1/M2 
-1 -1 1 1 -1.2 -1.2 7.44E
-05 
3.43
E-03 
A6NNI4 CD9 CD9 antigen -1.1 1.3 1.4 1.1 1.8 1.6 7.58E
-05 
3.43
E-03 
Q15067
-2 
ACOX Isoform 2 of 
Peroxisomal 
acyl-coenzyme 
A oxidase 1 
-1.2 1.2 1.5 1.1 1.4 1.3 8.71E
-05 
3.80
E-03 
B4DGP
8 
CANX Calnexin -1.1 -1 1 1.1 -1.3 -1.4 9.08E
-05 
3.82
E-03 
P31153 MAT2
A 
S-
adenosylmethi
onine synthase 
-1.1 -1 1.1 1.1 1.3 1.1 1.00E
-04 
4.07
E-03 
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isoform type-2 
P22307-
4 
SCP Isoform 4 of 
Non-specific 
lipid-transfer 
protein 
-1.1 -1.1 -1 1.3 1.7 1.3 1.08E
-04 
4.22
E-03 
P08195-
2 
SLC3
A 
Isoform 2 of 
4F2 cell-
surface antigen 
heavy chain 
-1 1.5 1.5 -1.1 -1.2 -1.1 1.20E
-04 
4.44
E-03 
P14866 HNRN
PL 
Heterogeneous 
nuclear 
ribonucleoprot
ein L 
-1 -1 1 1.1 -1.2 -1.3 1.21E
-04 
4.44
E-03 
A6NJG
9 
PSME
1 
Proteasome 
activator 
complex 
subunit 1 
-1 -1.1 -1.1 1 -1.6 -1.6 1.26E
-04 
4.51
E-03 
B3KS98 EIF3S
3 
Eukaryotic 
translation 
initiation 
factor 3 
subunit H 
1.1 -1.1 -1.2 1.1 -1.2 -1.3 1.35E
-04 
4.67
E-03 
Q9BR7
6 
CORO
1B 
Coronin-1B 1 1 -1 1.1 -1.3 -1.4 1.51E
-04 
5.07
E-03 
O14786
-2 
NRP Isoform 2 of 
Neuropilin-1 
-1.1 1 1.1 1.1 -1.5 -1.6 1.76E
-04 
5.74
E-03 
Q9Y3U
8 
RPL36 60S ribosomal 
protein L36 
-1 -1.1 -1.1 1 -1.3 -1.3 1.84E
-04 
5.86
E-03 
E7EUT
5 
GAPD
H 
Glyceraldehyd
e-3-phosphate 
dehydrogenase 
-1 -1 1 1.1 -1.3 -1.4 2.03E
-04 
6.23
E-03 
P00558 PGK1 Phosphoglycer
ate kinase 1 
-1.1 1 1.1 1.1 -1.3 -1.4 2.06E
-04 
6.23
E-03 
P68371 TUBB
4B 
Tubulin beta-
4B chain 
1 -1 -1 1.1 -1.1 -1.2 2.18E
-04 
6.42
E-03 
P11940-
2 
PABP
C 
Isoform 2 of 
Polyadenylate-
binding 
protein 1 
-1 -1 -1 1.1 -1.2 -1.3 2.36E
-04 
6.72
E-03 
Q15942 ZYX Zyxin -1 -1.1 -1.1 1.2 -1.2 -1.4 2.40E
-04 
6.72
E-03 
Q12906
-2 
ILF Isoform 2 of 
Interleukin 
enhancer-
binding factor 
3 
-1 -1 1 1.1 -1.2 -1.3 3.02E
-04 
8.28
E-03 
Q15067 ACOX
1 
Peroxisomal 
acyl-coenzyme 
A oxidase 1 
-1.1 1 1.1 1.1 -1.1 -1.2 3.14E
-04 
8.41
E-03 
Q16658 FSCN
1 
Fascin -1 -1 -1 1.1 -1.2 -1.4 3.53E
-04 
9.24
E-03 
E7EUT
4 
GAPD
H 
Glyceraldehyd
e-3-phosphate 
dehydrogenase 
-1 1 1 1.1 -1.2 -1.4 3.88E
-04 
9.92
E-03 
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P09429 HMG
B1 
High mobility 
group protein 
B1 
-1 1 1 1.2 -1.1 -1.3 4.31E
-04 
1.08
E-02 
E5RID6 DECR
1 
2,4-dienoyl-
CoA 
reductase, 
mitochondrial 
-1 -1.2 -1.2 1.2 -1.2 -1.4 4.62E
-04 
1.13
E-02 
P04406 GAPD
H 
Glyceraldehyd
e-3-phosphate 
dehydrogenase 
-1 -1 1 1.1 -1.2 -1.3 4.93E
-04 
1.18
E-02 
O00571
-2 
DDX3 Isoform 2 of 
ATP-
dependent 
RNA helicase 
DDX3X 
-1.1 -1.1 -1 1 -1.3 -1.3 5.31E
-04 
1.23
E-02 
B7Z6B8 DECR
1 
2,4-dienoyl-
CoA 
reductase, 
mitochondrial 
-1 -1.1 -1.1 1.2 -1.2 -1.4 5.36E
-04 
1.23
E-02 
Q5T7C6 HMG
B1 
High mobility 
group protein 
B1 (Fragment) 
-1 1 1 1.2 -1.1 -1.3 5.48E
-04 
1.23
E-02 
P00441 SOD1 Superoxide 
dismutase [Cu-
Zn] 
-1 1 1 1.1 -1.1 -1.2 5.54E
-04 
1.23
E-02 
B4DNL
6 
PRPS1 Ribose-
phosphate 
pyrophosphoki
nase 
1 -1 -1.1 1.1 -1.2 -1.3 5.84E
-04 
1.26
E-02 
O15372 EIF3H Eukaryotic 
translation 
initiation 
factor 3 
subunit H 
1.1 -1.1 -1.2 1.1 -1.2 -1.3 5.94E
-04 
1.26
E-02 
H0Y5E
8 
SAR1
A 
GTP-binding 
protein SAR1a 
(Fragment) 
1.1 1.1 -1 1.2 -1.2 -1.5 5.98E
-04 
1.26
E-02 
B4DQ1
9 
SAR1
A 
GTP-binding 
protein SAR1a 
1 1.1 1 1.2 -1.2 -1.5 6.60E
-04 
1.34
E-02 
P52292 KPNA
2 
Importin 
subunit alpha-
2 
1 1.1 1 1.1 1.2 1.1 6.70E
-04 
1.34
E-02 
K7ELJ7 CAPN
S1 
Calpain small 
subunit 1 
1.1 -1.1 -1.1 1.1 -1.2 -1.2 6.80E
-04 
1.34
E-02 
P40121-
2 
CAP Isoform 2 of 
Macrophage-
capping 
protein 
-1 -1.1 -1.1 1.1 -1.1 -1.2 6.86E
-04 
1.34
E-02 
A7MAP
0 
CORO
1C 
Coronin -1 -1 1 1.1 -1.2 -1.3 6.94E
-04 
1.34
E-02 
P68363 TUBA
1B 
Tubulin alpha-
1B chain 
1 1 -1 1.1 -1.2 -1.4 7.18E
-04 
1.36
E-02 
P30086 PEBP1 Phosphatidylet
hanolamine-
binding 
-1 1 1.1 1 -1.1 -1.1 8.05E
-04 
1.49
E-02 
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protein 1 
P06733 ENO1 Alpha-enolase -1 -1.1 -1 1 -1.2 -1.2 8.15E
-04 
1.49
E-02 
B1ALA
9 
PRPS1 Ribose-
phosphate 
pyrophosphoki
nase 1 
1 -1 -1.1 1.1 -1.2 -1.3 8.25E
-04 
1.49
E-02 
P04899-
4 
GNAI Isoform sGi2 
of Guanine 
nucleotide-
binding 
protein G(i) 
subunit alpha-
2 
1 1 -1 1.2 -1.2 -1.4 8.50E
-04 
1.52
E-02 
Q13630 TSTA
3 
GDP-L-fucose 
synthase 
1.1 1.4 1.3 1.1 -1.3 -1.4 1.05E
-03 
1.85
E-02 
P09104 ENO2 Gamma-
enolase 
-1 1.1 1.2 1.1 1 -1.1 1.11E
-03 
1.93
E-02 
J3KQ32 OLA1 Obg-like 
ATPase 1 
-1.2 1 1.2 1 -1.5 -1.5 1.13E
-03 
1.94
E-02 
H7C463 IMMT Mitochondrial 
inner 
membrane 
protein 
(Fragment) 
1.1 1.1 -1 1.1 -1.2 -1.3 1.19E
-03 
2.00
E-02 
P07737 PFN1 Profilin-1 -1.1 -1 1 1.1 -1.1 -1.2 1.24E
-03 
2.06
E-02 
P33316-
2 
DU Isoform 2 of 
Deoxyuridine 
5'-triphosphate 
nucleotidohydr
olase, 
mitochondrial 
-1 1.1 1.1 1.1 -1.3 -1.5 1.63E
-03 
2.66
E-02 
C9J406 IMMT Mitochondrial 
inner 
membrane 
protein 
1.1 1.1 -1 1.1 -1.2 -1.3 1.65E
-03 
2.66
E-02 
Q92597
-2 
NDRG Isoform 2 of 
Protein 
NDRG1 
-1 1.1 1.1 1.3 -1.2 -1.5 1.86E
-03 
2.93
E-02 
P22061-
2 
PCMT Isoform 2 of 
Protein-L-
isoaspartate(D-
aspartate) O-
methyltransfer
ase 
1.1 1 -1 1 -1.1 -1.1 1.87E
-03 
2.93
E-02 
P14618-
2 
PK Isoform M1 of 
Pyruvate 
kinase 
isozymes 
M1/M2 
-1 -1 1 1.1 -1.2 -1.3 1.93E
-03 
2.99
E-02 
F5GX11 PSMA
1 
Proteasome 
subunit alpha 
type-1 
1.1 1.2 1.1 -1 -1.2 -1.1 2.02E
-03 
3.05
E-02 
P55060- CSE1 Isoform 3 of -1.1 -1.1 -1 -1 -1.3 -1.2 2.05E 3.05
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3 Exportin-2 -03 E-02 
Q16891
-3 
IMM Isoform 3 of 
Mitochondrial 
inner 
membrane 
protein 
1.1 1.1 -1 1.1 -1.2 -1.3 2.05E
-03 
3.05
E-02 
C9J4N6 IDH1 Isocitrate 
dehydrogenase 
[NADP] 
cytoplasmic 
(Fragment) 
1 1 1 -1 -1.3 -1.2 2.20E
-03 
3.20
E-02 
G3V5P4 CFL2 Cofilin 2 
(Muscle), 
isoform 
CRA_d 
-1 1 1 1.1 -1.2 -1.3 2.22E
-03 
3.20
E-02 
J3QL06 HYOU
1 
Hypoxia up-
regulated 
protein 1 
(Fragment) 
1 -1.4 -1.4 1 1.2 1.1 2.23E
-03 
3.20
E-02 
H0YKK
6 
PSME
1 
Proteasome 
activator 
complex 
subunit 1 
1 -1 -1 -1.1 -1.4 -1.3 2.32E
-03 
3.29
E-02 
O60271
-3 
SPAG Isoform 3 of 
C-Jun-amino-
terminal 
kinase-
interacting 
protein 4 
-1.1 1 1.1 1.3 -1.1 -1.4 2.42E
-03 
3.31
E-02 
F8VSA
6 
NEDD
8 
NEDD8 -1 -1 -1 1.1 -1.1 -1.1 2.42E
-03 
3.31
E-02 
B4DDJ7 RAD2
3A 
UV excision 
repair protein 
RAD23 
homolog A 
1.1 1 -1 1.1 -1.4 -1.5 2.43E
-03 
3.31
E-02 
F8VRG
9 
PCBP2 Poly(rC)-
binding 
protein 2 
1 -1 -1 1.2 -1 -1.2 2.45E
-03 
3.31
E-02 
Q04637
-3 
EIF4G Isoform B of 
Eukaryotic 
translation 
initiation 
factor 4 
gamma 1 
-1 -1 -1 1.1 -1.1 -1.2 2.48E
-03 
3.32
E-02 
Q01105
-2 
SE Isoform 2 of 
Protein SET 
1 -1 -1 1.1 -1.2 -1.3 2.56E
-03 
3.33
E-02 
Q16891
-2 
IMM Isoform 2 of 
Mitochondrial 
inner 
membrane 
protein 
1.1 1.1 -1 1.1 -1.2 -1.3 2.61E
-03 
3.33
E-02 
P35754 GLRX Glutaredoxin-1 1 1 1 1.1 -1.3 -1.4 2.63E
-03 
3.33
E-02 
B7Z1R5 ATP6
V1A 
V-type proton 
ATPase 
-1 1.1 1.2 1.2 -1 -1.2 2.63E
-03 
3.33
E-02 
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catalytic 
subunit A 
F8W904 CSE1L Exportin-2 -1.1 -1.1 1 -1 -1.3 -1.2 2.64E
-03 
3.33
E-02 
P60891 PRPS1 Ribose-
phosphate 
pyrophosphoki
nase 1 
-1.1 -1 1.1 1.1 -1.2 -1.3 2.66E
-03 
3.33
E-02 
C9IZ80 BZW1 Basic leucine 
zipper and W2 
domain-
containing 
protein 1 
(Fragment) 
-1 1.1 1.1 1.2 -1.1 -1.3 2.74E
-03 
3.37
E-02 
Q8IVF2
-3 
AHNA
K 
Isoform 3 of 
Protein 
AHNAK2 
1 -1.1 -1.1 1.1 -1.1 -1.3 2.76E
-03 
3.37
E-02 
P17655 CAPN
2 
Calpain-2 
catalytic 
subunit 
1.1 1 -1.1 1.1 -1.1 -1.2 2.78E
-03 
3.37
E-02 
G3V1A
4 
CFL1 Cofilin 1 
(Non-muscle), 
isoform 
CRA_a 
-1.1 -1 1 1.1 -1.1 -1.3 2.84E
-03 
3.41
E-02 
P13640-
2 
MT1 Isoform 2 of 
Metallothionei
n-1G 
1.1 -1.2 -1.3 1.2 1.2 1 2.89E
-03 
3.44
E-02 
Q9BUF
5 
TUBB
6 
Tubulin beta-6 
chain 
1 1.1 1.1 1.2 1 -1.1 2.99E
-03 
3.52
E-02 
C9JIF9 APEH Acylamino-
acid-releasing 
enzyme 
-1 1.1 1.1 1.1 -1.2 -1.3 3.07E
-03 
3.58
E-02 
P08107 HSPA
1A 
Heat shock 70 
kDa protein 
1A/1B 
-1 1.4 1.5 1 -1.2 -1.2 3.11E
-03 
3.59
E-02 
P23526 AHCY Adenosylhomo
cysteinase 
-1 -1 -1 1.1 -1.1 -1.2 3.19E
-03 
3.65
E-02 
P05388 RPLP0 60S acidic 
ribosomal 
protein P0 
-1 1 1.1 1.2 -1.1 -1.3 3.34E
-03 
3.72
E-02 
P02452 COL1
A1 
Collagen 
alpha-1(I) 
chain 
-1 -1 -1 1.1 -1.2 -1.3 3.35E
-03 
3.72
E-02 
B4DVE
7 
ANXA
11 
Annexin -1 1.1 1.1 1.2 1.1 -1.1 3.35E
-03 
3.72
E-02 
P62942 FKBP
1A 
Peptidyl-prolyl 
cis-trans 
isomerase 
FKBP1A 
-1.1 1 1.1 1.1 -1.1 -1.2 3.38E
-03 
3.72
E-02 
P37837 TALD
O1 
Transaldolase -1 1 1 1.1 -1.1 -1.2 3.56E
-03 
3.87
E-02 
B4DU
W4 
SUMO
3 
Small 
ubiquitin-
related 
modifier 3 
1 -1.1 -1.2 1.3 1 -1.2 3.80E
-03 
4.09
E-02 
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P49411 TUFM Elongation 
factor Tu, 
mitochondrial 
1 1.1 1 1.3 -1.3 -1.7 3.83E
-03 
4.09
E-02 
O75396 SEC22
B 
Vesicle-
trafficking 
protein 
SEC22b 
-1 1.1 1.1 1.2 -1 -1.3 3.86E
-03 
4.09
E-02 
P62140 PPP1C
B 
Serine/threoni
ne-protein 
phosphatase 
PP1-beta 
catalytic 
subunit 
-1.1 -1.1 -1 -1 -1.2 -1.2 4.01E
-03 
4.20
E-02 
Q13642
-3 
FHL Isoform 3 of 
Four and a half 
LIM domains 
protein 1 
-1 1.1 1.1 1.2 1.2 -1 4.04E
-03 
4.20
E-02 
P22234 PAICS Multifunctiona
l protein 
ADE2 
1 1 1 1.1 -1.1 -1.2 4.10E
-03 
4.20
E-02 
Q8WU4
0 
CAM
K2G 
CAMK2G 
protein 
(Fragment) 
-1 1 1.1 1.1 -1.2 -1.3 4.11E
-03 
4.20
E-02 
Q04760 GLO1 Lactoylglutathi
one lyase 
-1.1 -1.1 -1 1 -1.3 -1.3 4.19E
-03 
4.25
E-02 
Q9BRA
2 
TXND
C17 
Thioredoxin 
domain-
containing 
protein 17 
1.1 1 -1.1 1.1 -1.2 -1.3 4.69E
-03 
4.67
E-02 
E9PPQ8 NASP Nuclear 
autoantigenic 
sperm protein 
(Fragment) 
1.1 -1.1 -1.1 1.1 1.2 1.1 4.70E
-03 
4.67
E-02 
Q9NYU
2-2 
UGGT Isoform 2 of 
UDP-
glucose:glycop
rotein 
glucosyltransfe
rase 1 
1.1 1.1 -1 -1 -1.5 -1.4 4.73E
-03 
4.67
E-02 
C9JE81 HADH
B 
3-ketoacyl-
CoA thiolase 
(Fragment) 
-1 -1.1 -1 1.1 -1.2 -1.4 4.76E
-03 
4.67
E-02 
O15231
-3 
ZNF18 Isoform 3 of 
Zinc finger 
protein 185 
-1 -1 -1 1 -1.3 -1.3 4.85E
-03 
4.72
E-02 
F5GWY
2 
ATIC Phosphoribosy
laminoimidazo
lecarboxamide 
formyltransfer
ase 
-1 1 1.1 1.1 -1.1 -1.2 4.92E
-03 
4.73
E-02 
P04075 ALDO
A 
Fructose-
bisphosphate 
aldolase A 
-1.1 1 1.1 1.1 -1.1 -1.2 4.94E
-03 
4.73
E-02 
Q9NUQ
9 
FAM4
9B 
Protein 
FAM49B 
-1 -1.1 -1.1 1 -1.3 -1.3 5.22E
-03 
4.92
E-02 
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Q9BXP
5-2 
SRR Isoform 2 of 
Serrate RNA 
effector 
molecule 
homolog 
1 1.2 1.2 1.2 -1 -1.2 5.24E
-03 
4.92
E-02 
D6RD6
6 
WDR1 WD repeat-
containing 
protein 1 
(Fragment) 
-1 -1 -1 1.2 -1.1 -1.3 5.27E
-03 
4.92
E-02 
C9JLK2 APEH Acylamino-
acid-releasing 
enzyme 
(Fragment) 
-1 1.1 1.1 -1.2 -1.6 -1.3 5.33E
-03 
4.94
E-02 
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Table 3-3 Differentially expressed proteins in cluster A and B. 
(*: t-test p≤0.05, **: t-test p≤0.01, n=5) 
Genes Protein name 
Log2 
FO/CN 
(day1) 
Log2 
OA/CN 
(day1) 
Log2 
FO/CN 
(day6) 
Log2 
OA/CN 
(day6) 
ANOVA 
p-value q-value 
Cluster 
A               
SCP2 Non-specific lipid-transfer protein -0.12 -0.10 0.75** 0.36** 
1.08E-
04 4.22E-03 
CD9 CD9 antigen 0.39 -0.10 0.81** 0.12 
7.58E-
05 3.43E-03 
ACOX 
Isoform 2 of Peroxisomal acyl-coenzyme A 
oxidase 1 0.25 -0.29 0.52** 0.14 
8.71E-
05 3.80E-03 
ACOX1 Acyl-coenzyme A oxidase 0.30 -0.28 0.55** 0.12 
7.29E-
05 3.43E-03 
SORD Sorbitol dehydrogenase 0.11 -0.09 0.59** 0.09 
1.97E-
07 1.16E-04 
COTL1 Coactosin-like protein 0.11 0.05 0.31* 0.19 
6.32E-
05 3.43E-03 
KPNA2 Importin subunit alpha-2 0.08 0.02 0.29* 0.17 
6.70E-
04 1.34E-02 
                
Cluster 
B               
APEH 
Acylamino-acid-releasing enzyme 
(Fragment) 0.11 -0.07 -0.67* -0.28 
5.33E-
03 4.94E-02 
TSTA3 GDP-L-fucose synthase 0.50* 0.12 -0.33* 0.12 
1.05E-
03 1.85E-02 
SLC3A 
Isoform 2 of 4F2 cell-surface antigen heavy 
chain 0.59** -0.02 -0.26 -0.18 
1.20E-
04 4.44E-03 
SQSTM1 Sequestosome-1 0.76** -0.06 0.24 0.18 
1.10E-
06 3.23E-04 
HSPA1A Heat shock 70 kDa protein 1A/1B 0.53** -0.05 -0.21 0.01 
3.11E-
03 3.59E-02 
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Table 3-4 IPA pathway analysis of cluster C 
Molecular and Cellular Functions   
Name p-value Number of 
Molecules 
Cellular Growth and Proliferation 6.61E-03 – 
2.26E-08 
28 
Cellular Movement  6.61E-03 – 
1.45E-06 
19 
Cellular Development 6.61E-03 – 
2.10E-06 
23 
Carbohydrate Metabolism  6.13E-03 – 
4.16E-06 
8 
Cellular Death and Survival  8.17E-03 – 
4.42E-05 
22 
   
Top Canonical Pathways   
Name p-value Overlap 
Glycolysis I (GAPDH, GPI, PGK1, PKM) 1.86E-07 4/25 (16%) 
Gluconeogenesis I (GAPDH, GPI, PGK1) 1.78E-05 3/25 (12%) 
Remodeling of Epithelial Adherens Junctions  
(TUBB3, TUBB4B, ZYX) 
3.65E-04 3/68(4.4%) 
EIF2 Signaling (EIF3H, PABPC1, PPP1CB, 
RPL36) 
5.49E-04 4/185 (2.2%) 
Breast Cancer Regulation by Stathmin1 (TUBB3, 
TUBB4B, PPP1CB, GNAI2) 
6.19E-04 4/191 (2.1%) 
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Table 3-5 Candidate targets of FO or OA treatment 
Protein 
ID 
Gene 
Name Protein name 
FC 
OA/CN 
MP 
OA/CN 
FC 
FO/CN 
MP 
FO/CN 
FC 
FO/OA 
MP 
FO/OA 
ANOVA q 
Value 
Day 1                   
E7EMC7 SQSTM1 Sequestosome-1 -1 0.7 1.7 0.0001 1.8 0.0001 0.0003 
                    
Day 6                   
P22307 SCP2 
Non-specific lipid-
transfer protein 1.3 0.005 1.7 0.0002 1.3 0.003 0.004 
Q16658 FSCN1 Fascin 1.1 0.08 -1.2 0.05 -1.4 
6.00E-
05 0.009 
B4DGP8 CANX Calnexin 1.1 0.3 -1.3 0.02 -1.4 0.001 0.004 
Q1L6U9 MSMP 
Prostate-associated 
microseminoprotein -1 1 -2 0.0009 -2 0.0008 2.12E-05 
 
FC: fold change 
MP: p value of multiple comparison test 
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Figure 3-1 Synthetic peptides served as quantification standards for MRM assays. 
To confirm the specificity of the assay, these synthetic peptides were spiked into each 
cell lysate with known quantities and monitored by MRM transitions. The cell lysate 
without the spiked peptide is labeled as “condition”, while the cell lysate with the spiked 
peptide is labeled as “spike in”. Spiked-in ratio: every 90 µl PC3 cell lysate sample 
(11.25 µg total protein) was spiked in 0.2 ng 23YLTAEAFGFK32 (FSCN1), 0.2 ng 
78GTLSGWILSK87 (CANX), 1.6 ng 52YFTLGESWLR61 (MSMP), 0.1 ng 48IGGIFAFK55 
(SCP2) and 1.6 ng 211HLTDAYFK218 (RPL6). For 20 µl protein was injected for each 
sample. 
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A. FSCN1, 23YLTAEAFGFK32, m/z 573.8 (M+2H+) → m/z 870.4  
 
Figure 3-2 XIC with (pink line) or without (blue line) spiked-in synthetic peptide in 
PC3 cell extracts. 
See Fig. 3-1 for relative quantity of each MRM peptide. (TIC: total ion chromatogram; 
XIC: extracted ion chromatogram) 
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B. CANX, 78GTLSGWILSK87, m/z 531.3 (M+2H+) → m/z 790.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   72 
 
 
C. MSMP, 52YFTLGESWLR61, m/z 636.3 (M+2H+) → m/z 747.4  
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D. SCP2, 48IGGIFAFK55, m/z 426.8 (M+2H+) → m/z 739.4  
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E. RPL6, 211HLTDAYFK218, m/z 497.8 (M+2H+) → m/z 744.4  
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F. chicken lysozyme, QA/QC sample, 40GYSLGNWVCAAK61, m/z 656.8 (M+2H+) → 
m/z 892.4 (no synthetic chicken lysozyme peptide was spiked-in in the sample)  
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Figure 3-3 Effects of FO and OA on PCa cell viability. 
A: MTT assay was measured 24-hr after PC3 cells were treated by control (0.1% ethanol), 
100 µM fish oil or 100 µM oleic acid (n=3). B: PC3 cells were seeded at 1000 cell/well in 
6-well plates, treated with control (0.1% ethanol), 100 µM FO, or 100 µM OA, 
respectively. Cells grew for approximately one week until the colonies were visible. Cells 
were fixed by methanol and stained with crystal violet (n=3). C: PC3 cell images 
captured during colony formation. D: Colony formation assay of LAPC4. LAPC4 cells 
were seeded at 3000 cell/well in 6-well plates. (n=3)  *:p<0.05 
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Figure 3-4 Effects of FO and OA on FASN activity in PC3 cells. 
Cells were seeded in 24-well cluster plates, treated with vehicle (0.1% ethanol), 100 µM 
FO or 100 µM OA for 3 days or 6 days. FASN activity was measured by 14C-acetate 
incorporation assay, in which the scintillation counts were normalized by cell counts in 
parallel treated wells (n=3). 
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Figure 3-5 Principal component analysis (PCA). 
A: PCA analysis of 127 significantly changed proteins (ANOVA p≤0.05, q≤0.05, n=5) 
shows graphic distribution of 30 samples (6 groups and 5 replicates in each) on axes of 
component 1 (F1) and component 2 (F2). B: By one minus Pearson Correlation, three 
major clusters were generated out of 73 proteins selected based on 127 proteins in (A) 
and has at least one significant change (t-test p≤0.05, n=5) in FO1/CN1 (fish oil vs. 
control, one-day), OA1/CN1 (oleic acid vs. control, one-day), FO6/CN6 (fish oil vs. 
control, six-day), or OA6/CN6 (oleic acid vs. control, six-day).  
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Genes Protein name 
Log2 
FO/CN 
(day1) 
Log2  
OA/CN 
(day1) 
Log2 
FO/CN 
(day6) 
Log2 
OA/CN 
(day6) 
ANOVA  
p value  q value 
GPI Glucose-6-phosphate isomerase 
0.05 
(NS) 0.03 (NS) -0.22
*
 
0.09 
(NS) 7.22E-05 
3.43E-
03 
GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
0.00 
(NS) 
-0.04 
(NS) -0.32
*
 
0.13 
(NS) 2.00E-04 
6.23E-
03 
PGK1 Phosphoglycerate kinase 1 
0.01 
(NS) 
-0.10 
(NS) -0.33
*
 
0.15 
(NS) 2.00E-04 
6.23E-
03 
PKM Pyruvate kinase isozymes M1/M2 
-0.04 
(NS) 
-
0.05(NS) -0.27
*
 
0.04 
(NS) 7.44E-05 
3.43E-
03 
PK 
Isoform M1 of Pyruvate kinase 
isozymes M1/M2 
-0.05 
(NS) 
-0.06 
(NS) -0.26
*
 
0.09 
(NS) 2.00E-03 
2.99E-
02 
 
Figure 3-6 Enzyme funtions in glycolysis/gluconeogenesis and its relative pathways 
are changed. 
Enzyme functions in glycolysis/gluconeogenesis and its relative pathways are changed. 
Differentially expressed glycolysis/gluconeogenesis proteins in cluster C (*: t-test p≤0.05, 
n=5) 
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Figure 3-7 MRM validation of expression changes of MSMP and SCP2. 
MRM validation of expression changes of MSMP (A), SCP2 (B) in FO or OA group 
compared to control, with internal control RPL6 (C) and spiked-in external control 
chicken lysozyme (D) (n=6). 
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Figure 3-8 Western Blot validation of expression changes of MSMP, SQSTM1 and 
autophagy marker LC3 I/II in FO or OA group. 
(A) SQSTM1 and β-actin; (B) Bar graph quantification of (A), n=3; (C) SQSTM-1 
mRNA level by RT-PCR (GUSB mRNA serves as internal standard), n=5; (D) Western 
blot of LC3 I/II from cells treated with different FAs in the presence of 8 µM CQ for 1 
day; (E) Bar graph quantification of (D), n=3; (F) secreted MSMP in medium; (G) Bar 
graph quantification of (F), n=3. 
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Figure 3-9 Expression of MSMP in other cell lines. 
PC3 CM and lysate were used as a positive control.  
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Figure 3-10 Proteasomal proteolysis activity detection by DQ-BSA under control, 
FO or OA treatment. 
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Chapter 4 Analysis of global phosphorylation changes induced by fish oil and oleic 
acid 
1 Introduction 
Cells respond to stress in various ways including the activation of survival 
pathways and the initiation of cell death.  For cell growth and survival, it is neither safe 
nor efficient to modulate protein functions by solely relying on de novo protein synthesis.  
PTMs, especially phosphorylation and dephosphorylation, can regulate signaling 
pathways quickly and reversibly, and thus it might be a more efficient survival strategy 
than de novo synthesis of proteins.  While the proteome profiling study provides an 
excellent opportunity to analyze the relative protein expression changes of thousands of 
proteins, the multitude of protein activities are primarily modulated by post-translational 
modifications, especially phosphorylation or dephosphorylation events.  It is estimated 
that as many as one-third of all mammalian cellular proteins are phosphorylated, resulting 
in the regulation of a wide array of cellular processes [209].  Indeed, the initiation of 
many signaling pathways often begins with phosphorylation of cell surface receptors, 
such as growth factor receptors [210].  Thus, further insight into the complex signal 
transduction pathways using unbiased discovery approaches will aid in elucidation of the 
underlying biological impact of FO on prostate cancer cell function.  In our previous 
global expression proteomics study [211], when prostate cancer cell line PC3 was treated 
with FO, cell viability suppression started as early as 24 hrs after the treatment.  
However, only a few proteins showed statistically significant changes in protein 
expression levels one day after the treatment.  This led us to hypothesize that post-
translational modifications, particularly phosphorylation or dephosphorylation events, 
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may play important roles in the metabolism of PUFAs in prostate cancer.  In this study, a 
model prostate cancer cell line, PC3, was treated with 100 µM FO, 100 µM OA or 
vehicle.  Cells were harvested 24-hr post-treatment and proteins were extracted, digested 
and enriched for phosphopeptides. An entire workflow of the study is shown in Fig. 4-1. 
 
2 Materials and methods 
1) Cell culture and fatty acid treatment 
Prostate cancer cell line PC3 (ATCC, Manassas, VA) was cultured in RPMI 
medium (Hyclone, Logan, UT) with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, 
MO), 100 µg/ml streptomycin and 100 U/ml penicillin (Lonza, Walkersville, MD) and 
incubated in 5% CO2 at 37°C. Fish oil (90% ethyl ester n-3 fatty acid: 40% DHA, 
40%EPA and 10% other n-3 PUFA) and oleic acid (90% oleic acid ethyl ester) (KD 
Pharma Bexbach GmbH, Berlin, Germany) were diluted into ethanol, making 100 mM 
stocks, which were added into complete medium at 0.1%, with a 100 µM final fatty acid 
concentration.  Cells were seeded in low density (170,000 cells per 100-mm culture dish) 
and treated with fatty acid the next day. Cells were harvested 24-hr post-treatment. 
2) Cell lysis, protein reduction, alkylation and digestion 
Cells were lysed (100 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100 and 5% 
glycerol), supplemented with 1% (v/v) phosphatase inhibitor (Sigma-Aldrich, St. Louis, 
MO) and 1% (v/v) protease inhibitor (Thermo-Fisher Scientific, Waltham, MA) (stock 
solution, 1 tablet into 1 mL H2O).  For each sample, 300 µg protein was taken for further 
sample prep and analysis, denatured with 50 mM TMAB containing 0.1% (w/v) RapiGest 
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surfactant (Waters, Milford, MA), followed by adding 10% (v/v) 1 M (NH4)2CO3, pH=11. 
Reduction and alkylation were carried out by incubating with cocktail mix solution 
consisting of acetonitrile, iodoethanol and triethylphosphine (195:4:1, v/v).  Digestion 
was performed by incubating overnight at 37°C with trypsin (Worthington Biochemical 
Corp, Lakewood, NJ) at a final concentration of 1:25 (w/w).  To remove RapiGest, 1/9 
volume of 1 M HCl was added to the sample to reduce pH to less than 3, then incubated 
at 37°C for 50 min, followed by centrifugation at 13,000 rpm.  Supernatant that contains 
all peptides (phosphorylated and non-phosphorylated) was saved for next steps.  Sample 
desalting was carried out through loading samples onto Silica C18 MacroSpin Columns 
(The Nest Group, Southborough, MA) followed by three washes in 5% ACN, 0.1% 
formic acid and finally eluted by 80% ACN, 0.1% formic acid.  The eluent was 
concentrated in a speed vacuum concentrator (Genevac, NY) until dry.  
3) Phosphopeptide enrichment 
Polymer-based Metal-ion Affinity Capture PolyMAC-Ti was used for 
phosphopeptide enrichment.  A PolyMAC-Ti agarose phosphopeptide enrichment kit was 
purchased from Tymora Analytical Operations (catalog#: AGARB, West Lafayette, IN) 
and enrichment was carried out according to manufacturer’s suggested protocol.  Briefly, 
dried sample peptides were first resuspended in loading buffer, mixed and incubated with 
PolyMAC-Ti reagent, then capture buffer was added into solution to adjust the pH 
between 5.5 and 6.5.  The mixture of PolyMAC-Ti and peptides was transferred to 
capture gel containing a spin column and incubated in a shaker for 10 min.  Non-binding 
peptides (non-phosphorylated) were discarded after spinning down the gel.  The gel was 
incubated with loading buffer in shaker, washed twice with washing buffer and once with 
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deionized water.  The phosphopeptides were eluted with elution buffer and dried in speed 
vacuum. 
4) Global phosphoproteomics analysis 
Data-dependent mass spectrometry (MS) analysis: Samples were reconstituted in 
5% ACN with 0.1% formic acid in water, loaded onto a micro-flow column (1.0mm x 
50mm, Tosoh Biosciences, King of Prussia, PA).  The eluting flow rate was at 50 µl/min 
with a linear gradient developed from 3% to 80% ACN over 120 min.  The eluents were 
directly sprayed into and analyzed by LTQ Orbitrap Velos Pro mass spectrometer 
(Thermo-Fisher Scientific, Waltham, MA).  A full scan FTMS with m/z ranging between 
350-2000; a follow-up ITMS scan was performed on the twelve top peaks selected.  CID 
activation was done on precursor ion with normalized collision energy set at 35.0%.  ESI 
conditions were set as follows: capillary temperature, 275°C; source heat temperature 
40 °C, sheath gas flow, 20 arbi units; auxiliary gas flow, 0 arbi unit; ESI source voltage, 5 
kV; the mass isolation width for CID was set at 2 m/z units. 
Data analysis: The acquired MS data were searched in a batch mode against a 
UniProt human database (version: Human 20130403) using X!Tandem.  Search 
parameters were set to locate differential modification of +79.96633 Da for 
phosphorylation.  Precursor ion tolerance was 10 ppm and product ion tolerance was ± 
1.0 Da.  The identified peptides and proteins were validated through PeptideProphet and 
ProteinProphet in the Trans-Proteomics Pipeline (TPP, v.4.6).  Peptides with 
probability >80% and proteins with probability over 90% are qualified for further 
analysis. IdentiQuantXLTM [152] was applied to perform label-free quantification. 
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5) Western blot  
Cells were harvested by scraping off the plate and cell pellets were lysed by lysis 
buffer consisting of 1% Triton-X100, 150 mM NaCl and 50 mM Tris, pH 7.6, 
supplemented with phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO) and protease 
inhibitor (Thermo-Fisher Scientific, Waltham, MA).  Protein concentration was measured 
by Bradford analysis.  Cell lysates were denatured by boiling in 1 volume of 2 x Laemmli 
buffer (Bio-Rad, Hercules, CA) supplemented with 5% beta-mercaptoethanol (Fisher 
Scientific, Pittsburgh, PA).  Proteins were loaded onto SDS-PAGE gel for separation and 
then transferred to PVDF membrane (Bio-Rad, Hercules, CA) at 100 mA for 120 min on 
ice.  PVDF membranes were blocked with 5% BSA (Roche, Indianapolis, IN).  Primary 
antibodies used were anti-phospho-PDHA1S232 (LifeSpan Biosciences, Seattle, WA), 
anti-phospho-PDHA1S293 (Emd Millipore Corporation, Billerica, MA), anti-phospho-
PDHA1S300 (Emd Millipore Corporation), anti-PDHA1 (Cell Signaling Technology, 
Danvers, MA) and anti-alpha-tubulin (Sigma-Aldrich, St. Louis, MO).  Secondary 
antibodies were also purchased from Cell Signaling Technology.  ImageJ, an open source 
Java image processing program inspired by NIH Image, was used to quantify bands. 
6) Pyruvate dehydrogenase (PDH) activity assay 
PDH activity was measured using PDH Enzyme Activity Dipstick Assay kit 
(catalog#: ab109882, Abcam, Cambridge, MA), in which PDH is captured by an antibody 
immobilized on a dipstick.  NADH produced by PDH reduces NBT to a colored 
precipitate.  Protein concentration of the cell lysate is determined by BCA assay, and in 
each experiment, the same amount of protein is loaded and the protein amount used is 
within the linear range of detection verified in the testing experiment (Fig. 4-2).  Each 
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experiment was carried out in duplicate dipsticks.  Band density was analyzed using 
ImageJ software.  Unpaired t-test was performed in five biological replicates.  
7) Bioinformatics and statics analysis 
The gene ontology networks were extracted using Biological Networks Gene 
Ontology tool (BiNGO) in Cytoscape platform.  Basic statistics (t-test, ANOVA and q-
value) analyses were performed using Graphpad 6.0, Excel and R based q-value analysis 
website (www.qvalue.princeton.edu). 
 
3 Results 
1) Global phosphorylation changes induced by FO and OA 
In this global phosphoproteomics discovery analysis, a total of 746 non-redundant 
phosphopeptides corresponding to 361 phosphoproteins were confidently identified with 
a FDR <1% (Fig. 4-3A & 3B). 
Observation frequency of certain phosphopeptides or phosphoproteins provides 
information of whether or not the phosphorylation is positively identified.  Label-free 
quantification also allows for the relative abundance comparison among these identified 
phosphopeptides under different treatment conditions based on peak intensity 
quantification using AUC of the phosphopeptides.  We evaluated the effects of both FO 
and OA on protein phosphorylation by combining and analyzing the values from both 
frequency and quantitation comparisons.     
When all the phosphopeptides were compared among control, FO-treated and 
OA-treated groups, 215 non-redundant phosphopeptides representing 165 
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phosphoproteins were identified in all three groups (Fig. 4-3A & 3B).  When the FO-
treated group and control group were compared, 194 phosphoproteins were in common. 
Thirty-seven other proteins were observed at least twice in the FO-treated group but not 
once in the control group, or at least twice in the control group but absent in the FO-
treated group (Table 4-1, List A).  Likewise, the OA-treated group and the control group 
had 199 phosphoproteins in common and 22 other proteins were observed at least twice 
in the OA-treated group but not once in the control group, or at least twice in the control 
group but absent in the OA-treated group (Table 4-1, List B). 
Gene ontology (GO) distribution was also carried out using BiNGO plug-in 
application on the Cytoscape platform.  This software provides visualization of 
overrepresented biological process categories after FDR corrections.  BiNGO parameters 
in this study were set as follows: Hypergeometric test and Benjamini & Hochberg FDR 
correction were applied to the analysis; significant cut-off was set to p≤0.05; whole 
annotation was used as reference set and GO Biological Process was used as the 
annotation file.  Protein list A, which was the phosphoprotein set differentially observed 
between the control and FO-treated groups, was analyzed using BiNGO.  Thirty-two 
genes encoding these proteins were overrepresented in the subcategories mainly 
concerning metabolic processes, cellular responses to stress, and cell death (Fig. 4-4).  
However, no enriched subcategories were overrepresented when using Protein list B, 
which is observed between the control and OA-treated groups. 
Peak-intensity based label-free relative protein quantification was performed on 
828 identified phosphopeptides, including some redundant phosphopeptides.  The 
comparison was carried out among different treatment groups.  As shown in Fig. 4-5A 
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and 5B, when the FO-treated group was compared with the control and the OA-treated 
group, 80 and 47 phosphorylation level changes greater than two-fold were observed with 
statistical significance (p≤0.05, n=4), respectively.  However, only a few minor changes 
were observed between the OA-treated and control groups (Fig. 4-5C).  
These observations indicate that FO induces more profound phosphorylation 
changes than OA, correlating well with cell viability suppression in prostate cancer cells 
one-day after the FO treatment from our previously published data [211].  
2) Key protein phosphorylation altered under treatment of FO or OA 
FO or OA modulation of cell signaling is suggested to be a multi-targeting and 
multi-level event.  In this study, we used very stringent criteria to select phosphopeptides 
with significant changes, including: 1) at least one of the three treatment groups was 
negative for a particular phosphopeptide (peptide frequency=0); 2) At least one of the 
other two groups had a phosphopeptide frequency ≥0.5; 3) ANOVA test, p≤0.05, q-
value≤0.05; 4) in one or more treatment group multiple comparison (corrected t-test), 
p≤0.05; and 5) fold-change ≥ 2.  Based on these stringent criteria, 12 non-redundant 
phosphopeptides representing 12 phosphoproteins showed significant changes in 
phosphorylation level among these treatment comparisons (Table 4-2 and Fig. 4-6).  
Although phosphorylation status may largely affect protein function [212] and 
many listed in Table 4-2 have been reported in the previous large-scale global 
phosphoproteomic studies [213-215], very few have been either validated or studied for 
site-specific functions.  In this study, one interesting observation is the elevated 
phosphorylation level of SQSTM1S366 (fold-change=3.7, q=0.001).  The phosphorylation 
site, serine-366, is located in the PEST domain [216], which is rich in proline (P), 
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glutamic acid (E), serine (S) and threonine (T) and considered to be associated with 
protein degradation [217].  However, whether the increased level of phosphorylation in 
this region is correlated with changes in SQSTM1 degradation remains to be investigated.  
It is worth noting that our previous study found up-regulation of SQSTM1 24-hr after the 
FO treatment at both the mRNA and protein levels [211], suggesting that the observed 
over-expressed protein level may not due to degradation.  
Another interesting protein, pyruvate dehydrogenase alpha 1 (PDHA1), was also 
detected with an altered phosphorylation state.  PDHA1 is a subunit of pyruvate 
dehydrogenase (PDH), which is a key enzyme involved in transforming pyruvate into 
acetyl-CoA and later being used in the tricarboxylic acid (TCA) cycle to carry out 
cellular respiration.  Phosphorylation levels on PDHA1S232 is considered to be inversely 
associated with its enzyme activity [218].  From this global phosphoproteomics study, 
PDHA1S232 was significantly suppressed upon FO treatment, suggesting that FO may 
interfere with carbohydrate metabolism by enhancing PDH activity to restore the 
glycolysis-TCA cycle connection. 
3) FO decreases phospho-PDHA1S232 and phospho-PDHA1S300 level and elevates 
PDH activity  
Pyruvate dehydrogenase activity is inhibited by phosphorylation of PDHA1 and 
reactivated by dephosphorylation [218].  To validate our observation from the LC/MS 
analysis (Fig. 4-7A), an independent set of samples consisted of three biological 
replicates were analyzed by Western blot using an anti-phospho-PDHA1S232 antibody.  
As shown in Fig. 4-7B, more than 80% phosphorylation on phospho-PDHA1S232 was 
suppressed by FO as compared to control or OA-treated group (p<0.05).  However, no 
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significant changes were observed between OA-treated and control groups (p=0.85) (Fig. 
4-7B and 4-7C) and total PDHA1 was not affected by the fatty acid treatment (Fig. 4-7B 
and 4-7D).  Besides phospho-S232, two other phosphosites, phospho-S293 and phospho-
S300 also participate in regulating PDHA1 activity.  In global study, phospho-S293 was 
only detected in one injection and phospho-S300 was not observed. Western Blot results 
show that FO can also suppress phospho-S300 but phospho-S293 is not significantly 
changed (Fig. 4-8).  The PDH activity was measured using an antibody-based Dipstick 
assay. As shown in Fig. 4-9A and 4-9B, PDH activity was significantly elevated by FO 
as compared to OA-treated group. 
4) Global phosphorylation changes induced by prolonged treatment of FO and OA 
Given that global proteomics study in prolonged FA treated PC3 cells reveals 
multiple molecular targets of FO, global phosphoproteomics discovery analysis was also 
performed in PC3 cells, which are treated for 6-days.  A total of 470 non-redundant 
phosphopeptides corresponding to 276 phosphoproteins were confidently identified with 
a FDR <1% (Fig. 4-10A & 10B).  117 phosphopeptides and 116 phosphoproteins were 
observed in all three treatments.  Quantitative analysis showed that after 6 days FO 
treatment, only two phosphopeptides with over two-fold change are significant compared 
to control (p≤0.05, n=4).  Noticeably, all the significantly changed phosphopeptides in 
OA groups (compared to either FO or control groups) are down-regulated (Fig. 4-11A & 
11B).   
Given that in this day-6 data set, no phosphopeptides have ANOVA test q 
value≤0.05, we used less stringent selection criteria than day-1 data set, including: 1) at 
least one of the three treatment groups was negative for a particular phosphopeptide 
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(peptide frequency=0); 2) At least one of the other two groups had a phosphopeptide 
frequency ≥0.5; 3) ANOVA test, p≤0.05; 4) in one or more treatment group multiple 
comparison (corrected t-test), p≤0.05; and 5) fold-change ≥ 2.  Based on these criteria, 6 
non-redundant phosphopeptides representing 6 phosphoproteins showed significant 
changes in phosphorylation level among these treatment comparisons (Table 4-3).  
 
4 Discussion 
Based on the data from our previous global expression profiling experiments, only 
a few proteins showed altered expression when control, FO-treated, and OA-treated 
groups were compared 24-hr post-treatment, implicating PTMs may play an important 
role in transmitting n-3 PUFA signals.  In this study, our goal was to globally profile the 
phosphoproteome to help understand how FO affects cellular functions of prostate cancer 
cells through regulating phosphorylation.  There have been studies suggesting that the 
phosphoproteome changes upon fatty acid stimulation [219, 220].  However, these 
previous studies were performed in yeast and no global phosphoproteome studies on fatty 
acid modulation of phosphoproteins have been carried out in mammalian cells.  This is 
the first study we are aware of that elucidates the global protein phosphorylation 
alterations with n-3 PUFA treatment in prostate cancer cells using a modern high-
throughput LC/MS platform.  
Among the proteins with phosphopeptide levels decreased by FO treatment, 
several have been well studied.  RRM2 is one of the enzymes responsible for DNA 
synthesis by turning ribonucleotides to deoxyribonucleotides.  RRM2S20 phosphorylation 
can be triggered by p34cdc2 kinase but mutations at Serine-20 cannot induce enzyme 
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activity alterations [221].  Another study showed that in addition to DNA synthesis 
functions, RRM2 can also inhibit the canonical Wnt/beta-catenin pathway and Wnt3a can 
phosphorylate RRM2S20 to reduce RRM2’s suppression of the Wnt pathway [222].  
Another protein, MCM3, functions in DNA replication and plays an important role in cell 
cycle checkpoint [223].  MCM3S711 and MCM3T722 were reported to be phosphorylated 
by cyclin E/Cdk2 in 293T cells [224].  The observed phosphorylation alterations in both 
RRM2 and MCM3 by FO may suggest a cell cycle suppression induced by FO.  The 
other two proteins among these down-phosphorylated proteins, SRRM1 and SRRM2, are 
members of the protein complex participating in pre-mRNA processing [225] and we 
suggest that they may be involved in rapid cell response to adjust biosynthesis under 
oxidative stress. 
Among the proteins with phosphopeptide levels elevated by FO treatment, 
AHNAK has been reported to induce arachidonic acid-dependent activation of 
phospholipase C-gamma1 [226].  Arachidonic acid is a n-6 PUFA, however, no studies to 
date have evaluated AHNAK functions with n-3 PUFA treatment.  Another over-
phosphorylated protein, DYNC1LI1, is a component of the cytoplasmic dynein 1 
complex, which helps microtubule dependent cargo trafficking [227].  Thus FO may 
induce changes in intracellular trafficking through function of DYNC1LI1.  Interestingly, 
DYNC1LI1 (cytoplasmic dynein 1) is also reported to interact with SQSTM1 [228], in 
which Ser-366 is up-regulated by FO.  SQSTM1 is a multi-functional protein, which also 
plays a critical role in polyubiquitinated substrate degradation during autophagy [229].  It 
is known that SQSTM1 itself is subjected to degradation in autophagy process [230], and 
Ser-366 locates to the PEST domain [216, 217], which may be associated with 
	   96 
degradation.  Whether the elevation of phospho-SQSTM1S366 is related to FO induced 
suppression of cell viability deserves further investigation. 
One important discovery from this study is down-regulation of phospho-
PDHA1S232, which may be a critical target of FO action. PDH complex is composed of 
three enzymes: E1 (PDH), E2 (dihydrolipoyl transacetylase or DLAT), and E3 
(dihydrolipoyl dehydrogenase or DLD) [231].  The E1 alpha subunit contains the E1 
active site and plays a key role in the function of the PDH complex, which connects 
glycolysis with tricarboxylic acid (TCA) cycle by converting pyruvate to acetyl-CoA and 
CO2.  It is already known that pyruvate dehydrogenase kinases and pyruvate 
dehydrogenase phosphatases (PDPs) regulate phosphorylation of PDHA1S232, 
PDHA1S293, and PDHA1S300 [232], which can also be induced by different 
chemotherapeutic drugs and UV treatment [233].  Western blot results showed that not 
only serine232 but also serine300 is downregulated by FO treatment, indicating that FO 
may regulate expression or activity of pyruvate dehydrogenase kinases or PDPs in PCa 
cells.  
As previously suggested by many studies, PDH activity is inhibited by 
phosphorylation of PDHA1 [218, 231, 234].  Consistent with other studies, we also 
observed an enhanced PDH activity when phospho-PDHA1S232 and phospho-PDHA1S300 
are down-regulated (Figs. 4-8 & 4-9).  A feature that most cancers adopt is altered 
metabolism often referred to as the Warburg effect that is characterized by accelerated 
aerobic glycolysis with an absence of the pyruvate product oxidation in mitochondria.  
Although, unlike other cancers, the main bioenergy source for prostate cancer cells are 
fatty acids instead of glucose [93], there is evidence indicating that glycolysis enzyme 
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expression is higher in prostate and many other cancers [235].  Several of the enzymes 
involved in glycolysis are also critical regulators of apoptosis and gene transcription, 
implicating that links between metabolic regulators, apoptosis, and gene transcription are 
established directly through the enzymes that control metabolism [236].  It is therefore 
not so surprising that glycolytic enzymes are suppressed by PUFAs [202, 203], and 
inhibition of glycolysis can elevate prostate cancer cell sensitivity toward stress [201].  
Our data suggest that FO might help partially restore TCA cycle function and normalize 
glucose metabolism in prostate cancer cells.  It is still unknown whether PDH activity 
induced by FO is connected to suppression of cell viability observed in our previous 
global expression study [211].  One report suggested that the elevated expression and 
activity of PDH are associated with inhibition of cell viability in other cancer cell lines 
[237] and inhibiting the pyruvate dehydrogenase kinases (e.g., by dichloroacetate) 
increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over 
glycolysis [238].  As the result, down-regulation of phosphorylation on PDH subunits 
suppresses tumor growth [238].  On the contrary, n-3 PUFAs have been suggested to 
increase pyruvate dehydrogenase kinase expression at the transcriptional level in muscle 
[239] and dendritic cells [240].  Whether PDH dephosphorylation participates in FO 
induced cell viability inhibition and how FO regulates pyruvate dehydrogenase kinases or 
PDPs still need to be investigated. 
Although OA does not seem to inhibit cell viability while FO does [211], it does 
alter a few protein phosphorylation changes in this global phosphoproteomic study (Fig. 
5-4C).  OA is known to inhibit VEGFR-1 autophosphorylation [241] and to induce ERK2 
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phosphorylation [242].  However, as compared to FO, OA showed much lower degree of 
activity in altering protein phosphorylation in prostate cancer cells. 
We present a large-scale global phosphoproteome analysis that utilized state-of-
the-art technologies.  Using an established cell line model, we show that phosphorylation 
changes induced by PUFAs can be quantitatively monitored by sensitive mass 
spectrometric methods.  Validation of phospho-PDHA1S232 levels by Western blot and 
assessment of phospho-PDHA1S300 level and PDH activity by a Dipstick assay also 
provide us increased confidence that metabolic-targeting approaches may be 
therapeutically valuable for prostate cancer management and prevention.  Additional 
studies investigating whether pyruvate dehydrogenase kinase, as well as identifying 
whether other PDPs are involved in pathway regulation by FO. 
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Table 4-1 Phosphoproteins differentially detected in fatty acid treated groups by 
observation frequency. 
List A: Phosphoprotein level change observed twice or more in the FO-treated group but 
absent in the control group, or twice or more in the control group but absent in the FO-
treated group. 
 
Protein 
ID 
Gene 
Name Protein Name 
Protein 
Frequency 
(Group C) 
Protein 
Frequency 
(Group F) 
Protein 
Frequency 
(Group OA) 
H3BV87 ARMCX3 
Armadillo repeat-containing X-linked 
protein 3 (Fragment) 0 0.5 0 
E7ESP2 CDK11A Cyclin-dependent kinase 11A 0.5 0 0.5 
P51397 DAP Death-associated protein 1 0.5 0 0.25 
E9PHI6 DYNC1LI1 
Cytoplasmic dynein 1 light intermediate 
chain 1 0 0.5 0 
E9PC74 EIF2B5 
Translation initiation factor eIF-2B 
subunit epsilon 0.5 0 0.25 
Q14315 FLNC Filamin-C 0.5 0 0.25 
C9J0Y3 GOLGA4 
Golgin subfamily A member 4 
(Fragment) 0 0.5 0 
E7EVX2 GOLGA4 
Golgin subfamily A member 4 
(Fragment) 0 0.5 0 
Q96RR5 HCA90 
Hepatocellular carcinoma-associated 
antigen 90 0 0.75 0 
P10809 HSPD1 
60 kDa heat shock protein, 
mitochondrial 0.5 0 0.75 
O43719 HTATSF1 HIV Tat-specific factor 1 0.5 0 0.25 
H0Y5W0 HUWE1 
E3 ubiquitin-protein ligase HUWE1 
(Fragment) 0.75 0 0.25 
P11717 IGF2R 
Cation-independent mannose-6-
phosphate receptor 0 1 0.5 
B4DTU4 LIG1 DNA ligase 0.5 0 0 
E9PLH4 LMO7 LIM domain only protein 7 0.5 0 0.75 
E9PMP7 LMO7 LIM domain only protein 7 (Fragment) 0.5 0 0.75 
E9PMS6 LMO7 LIM domain only protein 7 0.5 0 0.75 
H0Y424 LMO7 LIM domain only protein 7 (Fragment) 0.5 0 0.75 
C9J013 MCM2 
DNA replication licensing factor 
MCM2 (Fragment) 0.5 0 0.25 
H0Y9Z8 NCAPG 
Condensin complex subunit 3 
(Fragment) 0.5 0 0.25 
Q9ULX3 NOB1 RNA-binding protein NOB1 0.5 0 0.5 
C9JIG9 OXSR1 Serine/threonine-protein kinase OSR1 0 0.5 0 
E9PBS1 PAICS 
Phosphoribosylaminoimidazole 
carboxylase (Fragment) 0 1 0.5 
P08559 PDHA1 
Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, 
mitochondrial 0.75 0 0.5 
Q15124 PGM5 Phosphoglucomutase-like protein 5 0.5 0 0 
E9PJ24 PHRF1 PHD and RING finger domain- 0.5 0 0 
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containing protein 1 
H3BN34 PKM 
Pyruvate kinase isozymes M1/M2 
(Fragment) 0 0.75 0 
Q9NS91 RAD18 E3 ubiquitin-protein ligase RAD18 0.5 0 0 
D6RAD2 RFC1 
Replication factor C subunit 1 
(Fragment) 0.5 0 0.5 
C9J0A5 RNF20 
E3 ubiquitin-protein ligase BRE1A 
(Fragment) 1 0 0 
P31350 RRM2 
Ribonucleoside-diphosphate reductase 
subunit M2 0.5 0 0.25 
Q13501 SQSTM1 Sequestosome-1 0 0.75 0.25 
F6XM96 TFIP11 
Tuftelin-interacting protein 11 
(Fragment) 0 0.5 0 
E7ERH3 TNS3 Tensin-3 0.5 0 0.75 
A6NNK5 TP53BP1 
Tumor suppressor p53-binding protein 
1 0.75 0 0 
C9JXV0 TP53BP1 
Tumor suppressor p53-binding protein 
1 (Fragment) 0.75 0 0 
O43399 TPD52L2 Tumor protein D54 0 0.5 0 
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Table 4-1:  
List B: Phosphoprotein level change observed twice or more in the OA-treated group but 
absent in the control group, or twice or more in the control group but absent in the OA-
treated group.  
Protein 
ID 
Gene 
Name Protein Name 
Protein 
Frequency 
(Group C) 
Protein 
Frequency 
(Group F) 
Protein 
Frequency 
(Group OA) 
B4E0G4 PHF6 PHD finger protein 6 0 0.25 0.5 
B7Z8E4 CCNY Cyclin-Y 0 0 0.5 
E9PBS1 PAICS 
Phosphoribosylaminoimidazole carboxylase 
(Fragment) 0 1 0.5 
F5GYR8 USO1 General vesicular transport factor p115 0 0 0.5 
F5H7B0 SKIV2L Helicase SKI2W 0 0 0.75 
P11717 IGF2R 
Cation-independent mannose-6-phosphate 
receptor 0 1 0.5 
Q8WW12 PCNP 
PEST proteolytic signal-containing nuclear 
protein 0 0 0.5 
Q92625 ANKS1A 
Ankyrin repeat and SAM domain-containing 
protein 1A 0 0 0.5 
A6NNK5 TP53BP1 Tumor suppressor p53-binding protein 1 0.75 0 0 
B4DTU4 LIG1 DNA ligase 0.5 0 0 
C9J0A5 RNF20 
E3 ubiquitin-protein ligase BRE1A 
(Fragment) 1 0 0 
C9JXV0 TP53BP1 
Tumor suppressor p53-binding protein 1 
(Fragment) 0.75 0 0 
E9PJ24 PHRF1 
PHD and RING finger domain-containing 
protein 1 0.5 0 0 
H3BQ34 PKM Pyruvate kinase 0.75 0.75 0 
H3BUF6 ATXN2L Ataxin-2-like protein 0.5 0.25 0 
H7C3D5 FAM134A Protein FAM134A (Fragment) 0.5 1 0 
O00505 KPNA3 Importin subunit alpha-3 0.75 0.25 0 
O95218 ZRANB2 
Zinc finger Ran-binding domain-containing 
protein 2 0.5 0.25 0 
P51580 TPMT Thiopurine S-methyltransferase 0.5 0.5 0 
Q15124 PGM5 Phosphoglucomutase-like protein 5 0.5 0 0 
Q5VWV2 PARD3 Partitioning defective 3 homolog 0.5 0.25 0 
Q9NS91 RAD18 E3 ubiquitin-protein ligase RAD18 0.5 0 0 
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Table 4-2 Key phosphopeptides with significant changes 24 hours post-treatment. 
Protei
n ID 
Gene 
Name 
Protein 
Name 
Peptide 
Sequence 
Peptide 
Frequency 
(Group C) 
Peptide 
Frequenc
y (Group 
F) 
Peptide 
Frequenc
y (Group 
OA) 
FC_
F_C 
FC_
OA_
C 
FC_
OA_
F 
ANOV
A_p_va
lue 
 q-
value  
P3135
0 
RRM
2 
Ribonucle
oside-
diphospha
te 
reductase 
subunit 
M2 
VPLAPITDPQQL
QLSPLK 0.5 0 0.25 -7.8 -1.8 4.3 0.0009 0.009 
P0855
9 
PDH
A1 
Pyruvate 
dehydroge
nase E1 
componen
t subunit 
alpha, 
somatic 
form, 
mitochon
drial YGMGTSVER 0.75 0 0.5 -3 -1.2 2.4 0.001 0.009 
E9PL
H4 
LMO
7 
LIM 
domain 
only 
protein 7 
ATLSSTSGLDLM
SESGEGEISPQR 0.5 0 0.75 -2.6 -1.2 2.2 0.002 0.014 
F5GX
F7 
ZNF1
85 
Zinc 
finger 
protein 
185 
RESCGSSVLTDF
EGKDVATK 0.25 0 1 -1.8 1.2 2.2 0.01 0.030 
B4D
WW4 
MCM
3 
DNA 
replicatio
n 
licensing 
factor 
MCM3 
DGDSYDPYDFSD
TEEEMPQVHTPK 0.25 0.5 0 -2.3 -1.3 1.7 0.007 0.030 
Q9UL
X3 
NOB
1 
RNA-
binding 
protein 
NOB1 
KDDSDDDGGGW
ITPSNIK 0.25 0 0.5 -2.4 -1.5 1.6 0.001 0.009 
Q9U
Q35 
SRR
M2 
Serine/arg
inine 
repetitive 
matrix 
protein 2 
CRSPGMLEPLGS
SR 0 0.25 0.5 -2.1 -1.4 1.5 0.004 0.023 
Q8IY
B3 
SRR
M1 
Serine/arg
inine 
repetitive 
matrix 
protein 1 
KPPAPPSPVQSQS
PSTNWSPAVPVK
K 0.5 0 0 -2.6 -2.5 1.1 
8.00E-
06 0.001 
Q9Y6
G9 
DYN
C1LI
1 
Cytoplas
mic 
dynein 1 
KPVTVSPTTPTSP
TEGEAS 0 0.5 0 2 -1.2 -2.5 
3.00E-
05 0.001 
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light 
intermedi
ate chain 
1 
Q096
66 
AHN
AK 
Neuroblas
t 
differentia
tion-
associated 
protein 
AHNAK 
DDGVFVQEVTQ
NSPAAR 0 0.75 0 2.2 -1.3 -2.8 0.0003 0.006 
P2223
4 
PAIC
S 
Multifunc
tional 
protein 
ADE2 
TKEVYELLDSPG
K 0 0.75 0 2.2 -1.3 -2.8 0.002 0.014 
Q135
01 
SQST
M1 
Sequestos
ome-1 
EVDPSTGELQSL
QMPESEGPSSLD
PSQEGPTGLK 0 0.75 0.25 3.7 1 -3.6 
2.00E-
05 0.001 
(FC: Fold Change) 
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Table 4-3 Key phosphopeptides with significant changes 6-days post-treatment 
Protei
n ID 
Gene 
Name 
Protein 
Name Peptide Sequence 
Peptide 
Freque
ncy 
(Group 
C) 
Peptide 
Freque
ncy 
(Group 
F) 
Peptide 
Freque
ncy 
(Group 
OA) 
FC_F
_C 
FC_O
A_C 
FC_O
A_F 
ANOVA_p_
value 
Q1344
2 PDAP1 
28 kDa 
heat- and 
acid-stable 
phosphoprot
ein 
SLDSDESEDEEDDYQQ
K (Ser60) 0 0.5 0 1.8 -1.4 -2.6 0.03 
Q52L
W3 
ARHGA
P29 
Rho 
GTPase-
activating 
protein 29 
SFENVSVESVDSSSEK 
(Ser171) 0 0.5 0 1.4 -2.4 -3.3 0.009 
Q5H9
R7 PPP6R3 
Serine/threo
nine-protein 
phosphatase 
6 regulatory 
subunit 3 
IQQFDDGGSDEEDIWE
EK (Ser617) 0 0.5 0 1.2 -3.5 -4 0.02 
Q1545
9 SF3A1 
Splicing 
factor 3A 
subunit 1 
FGESEEVEMEVESDEE
DDKQEK (Ser329) 0.25 0 0.75 1.1 -2.3 -2.6 0.03 
Q86V
48 LUZP1 
Leucine 
zipper 
protein 1 
EKPDSDDDLDIASLVT
AK (Ser659) 0 0.5 0 -1.3 -3.1 -2.3 0.04 
Q9BQ
E3 
TUBA1
C 
Tubulin 
alpha-1C 
chain 
DYEEVGADSADGEDE
GEEY (Ser439) 0 0.5 0 1.4 -2.7 -3.8 0.007 
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Figure 4-1 Work-flow of the global phosphoproteomics study. 
PC3 cells were plated at 170K cells per 100 mm dish. After cells were attached for one 
day, culture medium was replaced with fresh medium supplemented with 100 µM FO, 
OA, or only vehicle (0.1% ethanol). Cells were harvested after 24 hours treatment. 
Protein was extracted and phosphopeptides were enriched using Polymac-Ti kit before 
LC/MS/MS analysis.  
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Figure 4-2 Linear range of PDH activity Dipstick assay. 
A: 165 µg, 82.5 µg, 41.25 µg, 20.6 µg protein in PC3 lysate were loaded on each dipstick. 
B: Linear regression was performed based on the protein amount on each dipstick and its 
corresponding band intensity. 
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Figure 4-3 Venn diagrams of identified phosphopeptides and corresponding 
phosphoproteins. 
A: Number of non-redundant phosphopeptide identified in at least 1 of 4 replicates under 
each condition. B: Number of corresponding phosphoproteins.  
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Figure 4-4 Biological network enrichment analysis of genes encoding differentially 
expressed phosphoproteins between control and FO treated cells. 
A gene list consisting of 32 genes was generated from 37 phosphoproteins with different 
phosphorylation levels with FO group and control comparisons. Yellow circles represent 
significant gene ontology categories overrepresented by gene sets with different p values. 
Analysis was performed using BiNGO in Cytoscape platform.  
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Figure 4-5 Relative comparisons of phosphopeptide levels based on label-free 
quantification. 
Fold change (y-axis) and t-test p-value (x-axis) were presented for each phosphopeptide 
(n=828). P-value axis crosses fold change axis at p=0.05. Relative changes with p-
value≤0.05 and fold change≥2 or ≤-2 were labeled in each figure by black dots (n=4). 
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Figure 4-6 Relative abundance of the significantly changed phosphoproteins under 
different treatment conditions. 
The relative abundance levels were calculated based on the phosphopeptide intensities 
with fish oil (FO)-treated, oleic acid (OA)-treated or control (C). (n=4) 
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Figure 4-7 Phosphoprotein validation of phospho-PDHA1S232. 
A: MS/MS spectrum of phosphopeptide 227YGMGTSVER235 from PDHA1S232; B: 
Western blot of phospho-PDHA1S232, total PDHA1, and α-tubulin, which served as a 
loading control; C: Bar graph of relative intensity of phospho-PDHA1S232 to a-tubulin, 
n=3 from Western blot of phospho-PDHA-1S232 (B); D: Bar graph of relative intensity of 
total PDHA1 to a-tubulin, n=3 from Western blot of PDHA1 (B). 
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Figure 4-8 Phosphoprotein phospho-PDHA1S293 and phospho-PDHA1S300. 
A: Western blot of phospho-PDHA1S293, phospho-PDHA1S300 and α-tubulin, which 
served as a loading control; B: Bar graph of relative intensity of phospho-PDHA1S293 to 
α-tubulin, n=3 from Western blot of phospho-PDHA1S293 (A); C: Bar graph of relative 
intensity of phospho-PDHA1S300 to α-tubulin, n=3 from Western blot of phospho-
PDHA1S300 (A) 
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Figure 4-9 PDH activity measurement. 
A: PDH activities measured by a dipstick assay kit; B: Quantitative bar graph of PDH 
activities from the dipstick assay (A), n=5. 
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Figure 4-10 Venn diagrams of identified phosphopeptides and corresponding 
phosphoproteins in day-6 FAs treatment. 
 
A: Number of non-redundant phosphopeptide identified in at least 1 of 4 replicates under 
each condition. B: Number of corresponding phosphoproteins.  
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Figure 4-11 Relative comparisons of phosphopeptide level based on label-free 
quantification in day-6 FAs treatment. 
Fold change (y-axis) and t-test p-value (x-axis) were presented for each phosphopeptide 
(n=518). P-value axis crosses fold change axis at p=0.05. Relative changes with p-
value≤0.05 and fold change≥2 or ≤-2 were labeled in each figure by black dots (n=4). 
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Chapter 5 Conclusions and future perspectives 
Previous studies on the effects of PUFAs on prostate cancer showed contradictory 
outcomes [98, 105], which make it difficult to classify certain dietary FAs as protective 
or detrimental supplements. Some studies were considered to have questionable 
experimental design [243-245].  This is further complicated by the heterogeneity of 
dietary FAs intake and corresponding FA composition in human bodies [246].  Dietary 
FAs can be subdivided into saturated and unsaturated FAs.  Among unsaturated FAs, 
omega-3, -6 or -9, and FAs with different length of carbon chain, have divergent 
functions.  Different kinds of food ingredients contain different FAs and different 
combinations of various FAs.  According to a systematic review of 37 studies, 
conclusions are inconsistent and unclear [119].  Studies carried out involve different FA 
measurements strategies, different populations and different endpoints of measurement.  
Most indications of PCa incidence are based on histological confirmation or medical 
record [96, 247].  Population of participants in these studies varies from hundreds [248]  
to thousands [249] and length of fish/fish oil consumption ranges from weeks [99] to 
years [250].  These studies also involved different FA measurement strategies.  One of 
the publications, which failed to support n-3 FAs’ protective role measured serum-
derived phospholipid FAs and the data was presented as percentage of each FA in total 
phospholipid FAs [105], while other studies measured FA composition in red blood cells 
[251] or prostatic tissues [98].  Many other papers, instead of evaluating body FAs levels, 
looked for correlation between fish consumption and PCa incidence [250, 252].  Some 
studies find that specific FAs rather than all FAs impact PCa risk.  For example, EPA [98] 
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and DHA [96] are reported to reduce PCa risk.  However, these studies also evaluated 
different endpoints.  According to a recent review [119], some studies measured PCa 
incidence as an endpoint of omega-3 PUFA’s impact on PCa [96] but some other studies 
measured PCa aggressiveness [250]. The contradictory conclusions suggest that FO may 
regulate many other undiscovered pathways and molecules, which may help explain the 
complexity of FO’s effects.   
 Compared to many other drugs, which have specific identified targets, FAs 
regulate cell function in a multi-target and multi-level fashion.  Previous studies found 
FO may exert its function by inducing survival stress [121], changing glucose 
metabolism [202], altering plasma membrane composition [253] or modulating 
inflammatory factors [254].  Our study identified several potential novel drug targets and 
pathways associated with FO action.  
In the global proteomic study, only very modest changes were discovered with 
FO treatment even with significant changes in cancer cell viability.  A possible 
explanation can be that in cell culture, PCa cells are exposed to abundant nutrients, which 
can be very different from the limited nutrients in the in vivo environment in which 
cancer grows.  In addition, FO consumed through the diet may be catabolized in vivo into 
additional compounds, which does not occur in an in vitro environment.  Some of the 
biologically important changes would need to be validated by other biochemical and/or 
biophysical methods.  
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1 FO induces survival-threatening stress in cancer cells 
N-3 PUFAs are reported to induce cytotoxicity by triggering reactive oxygen 
species (ROS) [121, 255, 256].  Our study confirmed that FO can inhibit viability in PC3 
cells within 24-hours after treatment.  However, the overall proteome profile under short-
term FO treatment condition (one day) did not change significantly as compared to 
prolonged treatment (i.e., six days).  After candidate selection using stringent criteria, the 
most significantly changed protein was sequestosome-1, ~1.7-fold overexpression 
induced by FO.  One reasonable assumption is that the increased level of sequestosome-1 
expression is the result of autophagy inhibition [189].  However, our follow-up study on 
autophagy showed that FO induced little change in LC3 II, biomarker of autophagy, 
indicating that FO had no direct effect on autophagy.  Our observation is not in 
agreement with a previously published study in which the authors suggested that DHA 
induces not only apoptosis but also autophagy [256].  Combined with our q-PCR results, 
which suggested that FO elevated sequestosome-1 expression at the transcriptional level, 
we hypothesize that FO-triggered stress induces accumulation of misfolded proteins and 
the accumulation rate exceeds the product elimination rate. Thus the FO treated cells 
need to synthesize more sequestosome-1, which directs the protein to be degraded via 
lysosomes.  Our study suggests the de novo synthesis instead of degradation inhibition is 
a more likely explanation for the accumulation of sequestosome-1 with FO treatment.  
Consistent with this, a report studying ovarian cancer chemo-resistance discovered that 
sequestosome-1 is upregulated in a drug-resistant cell line and relieved ROS stress 
induced by H2O2 [257].  From the phosphoproteome study, it was suggested that 
phospho-serine366 of sequestosome-1 was upregulated to as large as 3.7-fold.  Ser-366 is 
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located in the PEST domain, which is believed to be associated with degradation [217].  
However, we cannot conclude whether the induction of phosphorylation is due to the 
total protein level elevation, site-specific phosphorylation increase, or combination of 
both, given that the total protein level is up-regulated.  Considering that sequestosome-1 
was up-regulated at the transcriptional level, the protein over-expression is not the result 
of phosphorylation-dependent degradation changes.  Some proteins that regulate DNA 
synthesis or cell cycle, such as phospho-RRM2 and phospho-MCM3, also exhibited 
significant changes under FO treatment.  RRM2 is responsible for deoxyribonucleotide 
synthesis and FO significantly decreased RRM2S20 phosphorylation levels, which has 
been reported to be associated with Wnt pathway [222].  Through phosphorylating 
RRM2S20, Wnt3a can rescue the Wnt pathway from inhibition by RRM2.  Considering 
Wnt is one of the oncogenic pathways [258], our discovery that FO dephosphorylates 
RRM2S20 is consistent with the protective role of FO.  MCM3 is one of the proteins that 
control the cell cycle checkpoint and MCM3S711 phosphorylated by cyclin E/Cdk2 is 
down-regulated by FO [223, 224].  Taken together, when PC3 cells are treated with FO, 
the first wave of stress stimulated responses may include 1) synthesizing more 
sequestosome-1 to eliminate misfolded/unfolded proteins and 2) regulating 
phosphorylation level of cell cycle related proteins, such as RRM2 and MCM3, to block 
cell proliferation.  
 
2 FO influences the protein levels of glycolytic enzymes 
FAs are major components of living organisms.  Treatment with FAs lead to 
changes in default bioenergy regulation and metabolism.  It is clear that when extra FAs 
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are added into the medium in our experiments, the de novo synthesis pathway will be 
suppressed.  However, from our experimental results, FAs not only altered lipid but also 
glucose metabolism, even in PCa, in which glucose is not a main energy source.  The up-
regulation of aerobic glycolysis is considered as a hallmark in the progression of most 
tumors, and this phenomenon is known as the Warburg effect [259].  Our global 
proteome profile indicates several glycolysis/glycogenesis enzymes, including GPI, 
GAPDH, PGK1 and PK, are down-regulated after prolonged (6 days) FO treatment.  In 
addition to glycolysis processes, these proteins also play roles in other bioprocesses. 
GPI catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate.  
GPI is also known as autocrine motility factor (AMF).  Besides its role in glycolysis, 
GPI/AMF is a secreted cytokine and plays a critical part in metastatic cancers [260, 261].  
GPI/AMF can promote tumor growth and suppress apoptosis through activating 
PI3K/AKT and ERK pathways [262].  The expression of GPI/AMF has been found to be 
elevated in endometrial carcinoma [263].  In patients with clear cell renal cell carcinoma, 
highly expressed GPI/AMF is positively correlated with poor prognosis [264].   
GAPDH catalyzes the conversion of glyceraldehyde-3-phosphate to 1,3 
bisphospho-glycerate.  GAPDH is a house keeping protein and is used as an internal 
loading control for Western blotting in many studies.  However, its expression can be 
affected in some specific circumstances, such as with FO treatment in this study [265].  
Recent studies suggest that, like GPI, GAPDH is also a moonlighting protein with 
bioactivities other than the glycolytic role [266].  GAPDH participates in the fusion of 
vesicles [267] and organization of the cellular skeleton [268].  GAPDH is also discovered 
to modulate stabilization of mRNAs of some genes by binding to AU-rich elements in 3’-
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untranslated regions [269, 270].  In one prostate cancer study, GAPDH is shown to be a 
co-activator in AR dependent transactivation and this function is irrelevant to glycolysis 
[271]. 
PGK1 catalyzes 1,3 bisphosphate-glycerate to form glycerate-3-phosphate.  
Prostate cancer cells are reported to secret PGK1 to regulate bone formation at bone 
metastatic sites, by inducing osteoblastic differentiation and inhibiting osteoclastogenesis 
[272].  PGK1 secreted by stromal cells has also been shown to can promote prostate 
cancer growth and invasiveness [273].  
Pyruvate kinase was one of the proteins down-regulated and is involved in the 
transfer of phosphate groups from phosphoenolpyruvate to ADP to produce pyruvate and 
ATP.  High expression of PKM2 is observed in more advanced prostate cancer [274].  
Interestingly, another paper pointed out the nuclear translocation of PKM2 may induce 
epithelial-mesenchymal transition and promote metastasis of prostate cancer [275]. 
Our results suggest that expression levels of some glycolytic enzymes are 
suppressed by FO.  However, these changes are small but statistically significant.  
Furthermore, considering we did not evaluate the aerobic glycolysis rate, we cannot 
conclude that FO inhibits glycolysis in prostate cancer.  Further metabolic studies are 
needed to address this.  Some of these enzymes have additional functions other than 
serving in glycolysis and some of these functions are oncogenic [263, 271, 273, 275].  
Whether FO is capable of influencing the microenvironment distribution or subcellular 
localization of these enzymes would also be interesting to look into.   
While these protein level changes of glycolytic enzymes take place after 
prolonged treatment (six-days) of FO, shorter incubation with FO (one-day) also triggers 
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changes related to glucose oxidation.  Pyruvate can be broken down into acetyl-CoA by 
PDH enzymes, which link the glycolysis and the TCA cycle. In turn, PDH is regulated by 
pyruvate dehydrogenase kinases (PDK) through phosphorylation and inactivation, and 
pyruvate dehydrogenase phosphatase through dephosphorylation and activation.  In our 
phospho-proteome study, after the first day of FO treatment, phospho-pyruvate 
dehydrogenase A1 (phospho-PDHA1S232) was down-regulated, while PDH activity was 
found to be increased.  Meanwhile in this phosphoproteome study, for the other two 
phosphorylated sites, phospho-PDHA-1S293 is also down-regulated in FO group compared 
to control (fold change = -1.3, p=0.03) though the change is not significant when 
analyzed by Western blot while phospho-PDHA-1S300 had not been identified in the 
phosphoproteome study but was found suppressed in Western blot analysis.  The 
combination results of the proteome and phospho-proteome studies implicate that FO 
treatment may suppress the glycolytic pathway by restoring the connection between the 
glycolysis product, pyruvate, with TCA cycle through dephosphorylating PDHA1 at 
serine-232 and serine-300 and elevating the enzyme activity in short-term treatment 
while suppressing glycolysis enzyme expression level after long-term treatment.   
 
3 FO alters plasma membranes, intracellular trafficking and cytoskeleton 
Dietary FA intake changes the composition of plasma membranes [253].  There 
are two aspects it may affect.  First, it may alter the microenvironment by affecting the 
lipid raft holding the membrane attaching proteins, many of which are key cell signal 
transducing molecules [276, 277].   Second, based on our study, it may change the 
normal cargo trafficking by affecting the intracellular vehicle membrane and the 
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associated proteins.   Our phosphoproteome study found that FO changes 
phosphorylation of phospho-DYNC1LI1 (cytoplasmic dynein 1 light intermediate chain 
1), a protein involved in intracellular transportation [278].  It is worth noting, according 
to our day-6 FO treatment global proteomic study results, many cell skeleton proteins, 
such as tubulin (including tubulin beta-3 chain, fold change = -1.2, p=0.01; tubulin alpha-
4A chain, fold change= -1.2, p=0.07), vimentin (fold change = -1.2, p=0.03) and keratin 
(fold change = -1.2, p=0.05), are all down-regulated by FO.  
 
4 FO alters pro-inflammatory pathways 
N-3 PUFAs are considered to be anti-inflammatory and anti-oncogenic [279-281].  
Besides known anti-inflammatory metabolites, such as PGE3 or LTB5 [282], our study 
also reveals its suppressive function on a recently identified inflammatory molecule 
MSMP (prostate associated microseminoprotein), which is a strong ligand for CCR2B 
[207].  This discovery not only gives new insight into FO’s anti-inflammatory effect but 
also suggest that MSMP might be a potential biomarker to monitor FO’s effect on PCa.  
In addition, as MSMP is a secreted protein, it might be able to be detected in body fluid, 
such as plasma or prostate secretion and serve as a novel biomarker for detection of 
primary PCa or disease relapse.  Follow-up studies could be carried out to measure 
MSMP levels in plasma or urine of patients with different PCa stage and clinical trials 
can also be performed to check whether MSMP levels are changed before and after 
treatment.  
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5 FASN expression may regulate pro-inflammatory prostaglandin production 
FAs produce numerous bioactive metabolites including prostaglandins, 
thromboxanes and leukotrienes through enzymes such as LOXs and COXs [283].  Some 
of these metabolites are pro-inflammation/pro-oncogenic and others may have opposing 
functions [284, 285].  Previous studies showed that metabolites of n-6 PUFAs are more 
inflammatory compared to those of n-3 PUFAs.  What adds to the complexity is that in 
different environments the enzyme expression and activity may differ [150, 286].  In 
addition to this, these enzymes can be regulated by different FAs similar to that of COX-
2 expression altered by increased n-3/n-6 PUFA ratios [158].  Our studies find a 
regulatory connection between COX-2 and FASN that COX-2 expression is decreased 
when FASN is depleted.  Considering that the only known function of FASN is 
synthesizing palmitate, whether the regulation is direct or indirect still needs additional 
investigation.  As both FASN and COX-2 are overexpressed in cancer cells [53, 150], are 
both related to inflammation and down-regulated by n-3 PUFAs, the discovery that 
FASN protein depletion can lead to COX2 decrease may render another explanation for 
FO anti-inflammatory effects.   
The FASN siRNA knockdown study also explored additional potential targets of 
FASN.  The purpose and concept of studying the pathways modulated by FASN is 
similar to the FA study, with the hypothesis that FASN knockdown would dramatically 
change pathways modulated by fatty acid synthesis products.  In our study of FASN in 
PC3, there is only a partial suppression of pathway activity by FO although the 
expression change is significant.  This may lead to limited downstream target changes.  
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The outcome of our study suggests that even when total protein levels are suppressed, 
some functional residual FASN proteins may remain active. 
 
6 Limitations and future directions  
Like many studies, there are limitations to our studies.  1) Proteins with critical 
roles may not be detected due to their low abundance, which is beyond the detection limit 
of the mass spectrometry.  2) Many proteins we identified have changes that are 
statistically significant but have small changes.  In addition to the assumption we made 
that expressions of certain proteins are changed, it is also possible that FO exerts its 
function through other mechanisms.  Besides the probable alterations on PTM, it is also 
possible that the bioactive metabolites of FO change the biological processes in the cells.    
Many metabolites of FO, such as PGE3, 15-HEPE and LTB5 are proved to be anti-
inflammatory or anti-mitogenic [282, 287, 288].  3) The functions of the majority of the 
phosphorylation sites are not well characterized, which limits the ability to analyze the 
causative factors.  4) The molecular targets and pathways regulated by FO are only 
identified in one PCa cell line, PC3.  To find out if these changes are universal and 
cancer-specific, it is necessary to validate these results in other prostate cancer cell lines, 
benign prostate cells and cell lines from other cancer types.  5) This study was carried out 
only in in vitro conditions.  In vivo studies are needed to validate the discoveries made in 
these studies, i.e., in animal models and clinical trials.  
To conclude, our studies investigated both global proteome changes and global 
phosphoproteome changes modulated by FO and OA.  Cross comparison of the two 
proteome-wide studies and follow-up protein expression/function verification 
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experiments confirmed the potential targets associated with the PUFA treatment and that 
were specific to FO treatment.  In addition, the analysis of the time-course study 
dissected out complex regulatory pathways into less complicated step-wise functions 
altered by FO over time.  This study confirmed that FO changed PCa cell function 
through diverse pathways including glycolysis, cell cycle, cytotoxicity induced stress, 
anti-inflammation and also provided useful details about the mechanism of these effects 
by identifying novel protein and phosphoprotein targets such as MSMP, phospho-
sequestosomeS366 and phospho-PDHA1S232, S300 (Fig. 5-1).  This study also discovered an 
interesting regulatory connection between FASN and COX2.  Considering the success of 
the combination of global proteomic and phosphoproteomic studies to identify new 
important proteins altered by FA treatment in PC3 cells, a global proteome and 
phosphoproteome clinical study in PCa patients would validate and extend these findings 
to the patient population and potentially identify additional targets of FO action, 
providing novel opportunities for therapeutic development.  
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Figure 5-1 Multiple pathways in PC3 cell line are regulated by fish oil treatment. 
Multiple proteins involved in multiple biological processes including cytotoxicity 
induction, inflammation suppression, and glycolysis inhibition, PDH activation were 
altered after the fish oil treatment. 
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